



13 **Abstract**

14 In embryos, multipotent progenitors divide to produce distinct progeny and express  
15 their full potential. In vertebrates, multipotent cardiopharyngeal progenitors produce  
16 second-heart-field-derived cardiomyocytes, and branchiomic skeletal head muscles.  
17 However, the mechanisms underlying these early fate choices remain largely elusive.  
18 The tunicate *Ciona* emerged as an attractive model to study early cardiopharyngeal  
19 development at high resolution: through two asymmetric and oriented divisions,  
20 defined cardiopharyngeal progenitors produce distinct first and second heart  
21 precursors, and pharyngeal muscle (aka atrial siphon muscle, ASM) precursors. Here,  
22 we demonstrate that differential FGF-MAPK signaling distinguishes between heart and  
23 ASM precursors. We characterize a feed-forward circuit that promotes the successive  
24 activations of essential ASM determinants, *Hand-related*, *Tbx1/10* and *Ebf*. Finally, we  
25 show that coupling FGF-MAPK restriction and cardiopharyngeal network deployment  
26 with cell divisions defines the timing of gene expression and permits the emergence of  
27 diverse cell types from multipotent progenitors.

28

## 29 **Introduction**

30 Developmental genetics knowledge guided progress towards driving mammalian  
31 stem cells into forming pure cultures of selected cell types *in vitro* (e.g. ([Kattman et al.,](#)  
32 [2011](#); [Mazzoni et al., 2011](#); [Peljto and Wichterle, 2011](#)). By contrast, in the embryo,  
33 pluripotent cells generate diverse cell types in defined proportions, as they divide before  
34 individual daughter cells adopt distinct fates.

35 Subsets of the heart and head/neck myocytes recently emerged as related  
36 derivatives of multipotent progenitors located in the cardiopharyngeal mesoderm  
37 ([Diogo et al., 2015a](#); [Tzahor, 2009](#); [Tzahor and Evans, 2011](#)). Early lineage tracing,  
38 transplantations and controlled explant culture experiments demonstrated that the  
39 anterior splanchnic/pharyngeal mesoderm of amniote embryos can produce either  
40 skeletal muscles or heart tissue, depending upon exposure to growth factors and  
41 signaling molecules ([Nathan et al., 2008](#); [Tirosh-Finkel et al., 2006](#); [Tzahor et al., 2003](#);  
42 [Tzahor and Lassar, 2001](#)). Clonal analyses in the mouse further revealed the existence  
43 of common *Mesp1*-expressing progenitors for subsets of the second heart field-derived  
44 cardiomyocytes and branchiomic facial, jaw, neck and even oesophageal muscles  
45 ([Gopalakrishnan et al., 2015](#); [Lescroart et al., 2014](#); [Lescroart et al., 2015](#); [Lescroart et](#)  
46 [al., 2010](#); [Lescroart et al., 2012](#)). In pluripotent stem cells, controlled *Mesp1* expression  
47 can drive mesodermal progenitors towards cardiac and/or skeletal muscle fates  
48 ([Bondue et al., 2008](#); [Chan et al., 2016](#); [Chan et al., 2013](#)). Proper development of the  
49 pharyngeal apparatus and second heart field derivatives require shared inputs from  
50 *Tbx1*, *Nkx2.5* and *Islet1* transcription factors (e.g. ([Cai et al., 2003](#); [George et al., 2015](#);  
51 [Jerome and Papaioannou, 2001](#); [Kelly et al., 2004](#); [Merscher et al., 2001](#); [Mosimann et](#)  
52 [al., 2015](#); [Nevis et al., 2013](#); [Prall et al., 2007](#); [Tzahor and Evans, 2011](#); [Vitelli et al.,](#)  
53 [2002a](#); [Watanabe et al., 2012](#); [Witzel et al., 2017](#); [Yagi et al., 2003](#); [Zhang et al., 2006](#))).  
54 Taken together, this growing body of evidence points to the existence of a mesodermal

55 field of multipotent progenitors capable of producing either SHF-derived  
56 cardiomyocytes or branchiomeric skeletal muscles in early vertebrate embryos ([Diogo et](#)  
57 [al., 2015b](#); [Mandal et al., 2017](#)). However, the mechanisms that distinguish fate-  
58 restricted heart and head muscle precursors remain largely elusive.

59 The tunicate *Ciona*, which is among the closest living relatives to the vertebrates  
60 ([Delsuc et al., 2006](#); [Putnam et al., 2008](#)), has emerged as a simple chordate model to  
61 characterize multipotent cardiopharyngeal progenitors and the mechanisms that  
62 initiate heart vs. pharyngeal muscle fate choices ([Kaplan et al., 2015](#); [Razy-Krajka et al.,](#)  
63 [2014](#); [Stolfi et al., 2010](#); [Tolkin and Christiaen, 2016](#); [Wang et al., 2013](#)). *Ciona* tailbud  
64 embryos possess two multipotent cardiopharyngeal progenitors on either side. Like  
65 their vertebrate counterparts, these cells emerge from *Mesp*+ progenitors towards the  
66 end of gastrulation; they are induced by FGF-MAPK signaling and have been termed  
67 *trunk ventral cells* (aka TVCs; ([Christiaen et al., 2008](#); [Davidson and Levine, 2003](#);  
68 [Davidson et al., 2006](#); [Davidson et al., 2005](#); [Satou et al., 2004](#); [Stolfi et al., 2010](#))).  
69 TVCs activate conserved cardiac markers, including *Hand*, *Gata4/5/6* and *Nk4/Nkx2-5*,  
70 and migrate as polarized pairs of cells, until the left and right pairs meet at the ventral  
71 midline and begin to divide asymmetrically along the mediolateral axis (Figure 1A;  
72 ([Christiaen et al., 2008](#); [Davidson et al., 2005](#); [Satou et al., 2004](#); [Stolfi et al., 2010](#))).  
73 The first oriented asymmetric divisions produce small median first heart precursors  
74 (FHPs), and large lateral second trunk ventral cells (STVCs), which specifically activate  
75 *Tbx1/10* ([Davidson et al., 2005](#); [Stolfi et al., 2010](#); [Wang et al., 2013](#)). STVCs later divide  
76 again to produce small median second heart precursors (SHPs), and large lateral atrial  
77 siphon muscle founder cells (ASMFs), which activate *Ebf* (aka *COE*; ([Razy-Krajka et al.,](#)  
78 [2014](#); [Stolfi et al., 2010](#); [Stolfi et al., 2014c](#))). The transcription factors Hand-related  
79 (Hand-r)/*Notr1c*, which is expressed in the TVCs and maintained in the STVCs and  
80 ASMFs after each division, and *Tbx1/10* are required for *Ebf* activation in the ASMFs,

81 whereas Nk4/Nkx2.5 represses *Tbx1/10* and *Ebf* expression in the second heart  
82 precursors (SHPs)([Razy-Krajka et al., 2014](#); [Tolkin and Christiaen, 2016](#); [Wang et al.,](#)  
83 [2013](#)). Conversely, *Tbx1/10* and *Ebf* inhibit cardiac markers, and likely determinants,  
84 such as *Gata4/5/6* and *Hand* ([Razy-Krajka et al., 2014](#); [Stolfi et al., 2010](#); [Stolfi et al.,](#)  
85 [2014a](#); [Wang et al., 2013](#)). These regulatory cross-antagonisms underlie the transition  
86 from transcriptionally primed multipotent progenitors to separate fate-restricted  
87 precursors, by limiting the deployment of the heart- and pharyngeal-muscle-specific  
88 programs to their corresponding specific precursors ([Kaplan et al., 2015](#)).

89 Here, we identify regulatory mechanisms ensuring the emergence of diverse fate-  
90 restricted precursors from multipotent progenitors. We show that differential FGF-  
91 MAPK signaling, feed-forward regulatory circuits and coupling with the cell cycle  
92 control the spatially restricted activation of *Tbx1/10* and *Ebf*, successively, thus  
93 permitting the emergence of both first and second heart precursors, and  
94 ASM/pharyngeal muscle precursors from common multipotent progenitors.

95

96 **Results**

97 **MAPK signaling is active in the multipotent cardiopharyngeal progenitors**  
98 **and progressively restricted to the pharyngeal muscle precursors.**

99 During the earliest stages of cardiopharyngeal development in ascidians,  
100 multipotent progenitors display multilineage transcriptional priming, ([Razy-Krajka et](#)  
101 [al., 2014](#); [Stolfi et al., 2014b](#)), and subsequent regulatory cross-antagonisms segregate  
102 distinct cardiopharyngeal programs to their corresponding fate-restricted progenitors  
103 ([Stolfi et al., 2010](#); [Wang et al., 2013](#)); reviewed in ([Kaplan et al., 2015](#))). For instance,  
104 the ASM-specific factor *Ebf* is necessary and sufficient to terminate the heart program  
105 and impose a pharyngeal muscle fate ([Razy-Krajka et al., 2014](#); [Stolfi et al., 2010](#)).  
106 However, the symmetry-breaking events leading to cardiopharyngeal mesoderm  
107 patterning and ASM-specific expression of *Ebf* remain unknown. We surmised that  
108 differential signaling inputs determine the stereotyped spatio-temporal patterning of  
109 early cardiopharyngeal progenitors.

110 The *Ciona* homologs of specific FGF-MAPK pathway components, including *FGF*  
111 *receptor substrate 2/3* (*Frs2/3*; ([Gotoh et al., 2004](#))), *Ets.b*, and *Fgf4/5/6*, are  
112 preferentially expressed in the TVCs, in the STVCs and in the ASMFs as cells transition  
113 from multipotent progenitor to distinct heart vs. ASM fate-restricted states ([Razy-](#)  
114 [Krajka et al., 2014](#)). These patterned expressions of MAPK effector genes prompted us  
115 to evaluate a role for FGF-MAPK pathway in cardiopharyngeal fate decisions.

116 We first used an antibody specific to the dual phosphorylated form of Extracellular  
117 Regulated Kinase (dpERK) to monitor Mitogen Activated Protein Kinase (MAPK)  
118 activity in the cardiopharyngeal mesoderm. We detected dpERK staining in the newly  
119 born TVCs, marked by the B7.5-lineage-specific *Mesp>H2B::mCherry* transgene  
120 (Figure S1), as previously observed (Davidson et al, 2006). We also detected weaker but

121 persistent dpERK staining in the TVCs during migration (Figures 1 and S1). Following  
122 the first and second asymmetric divisions of the TVCs and STVCs, dpERK staining was  
123 successively restricted to the more lateral STVCs and ASMFs, respectively (Figures 1A,  
124 B; S1).

125

126 **The canonical FGF/Ras/MEK/ERK pathway is necessary and sufficient to**  
127 **promote pharyngeal muscle specification in the cardiopharyngeal lineage.**

128 This exclusion of MAPK activity from the medial first and second heart precursors  
129 opened the possibility that differential ERK activity is required for proper STVC and  
130 ASMF vs. heart precursors fate decisions. In *Ciona*, signaling through the sole FGF  
131 receptor (FGFR) governs ERK activity in several developmental processes, including  
132 neural induction ([Bertrand et al., 2003](#); [Hudson et al., 2003](#)) and central nervous  
133 system patterning ([Haupaix et al., 2014](#); [Racioppi et al., 2014](#); [Stolfi et al., 2011](#); [Wagner](#)  
134 [et al., 2014](#)), early endomesoderm and notochord fate specification ([Imai et al., 2002](#);  
135 [Picco et al., 2007](#); [Shi and Levine, 2008](#); [Shi et al., 2009](#); [Yasuo and Hudson, 2007](#)).  
136 Notably, FGF-MAPK signaling is active in the *Mesp*<sup>+</sup> cardiogenic B7.5 blastomeres  
137 ([Imai et al., 2006](#); [Shi and Levine, 2008](#)), where targeted misexpression of a dominant  
138 negative form of FGFR (dnFGFR) blocks TVC induction ([Christiaen et al., 2008](#);  
139 [Davidson et al., 2006](#)). We used a TVC-specific *Foxf* enhancer (*Foxf(TVC):bpFog-*  
140 *1>dnFGFR::mCherry*, hereafter called *Foxf>dnFGFR*; ([Beh et al., 2007](#))), to bypass  
141 early effects and achieve later misexpression of dnFGFR in the TVCs and their progeny.  
142 Importantly, although TVC fate specification and the onset of *Foxf* expression require  
143 FGF-MAPK signaling ([Beh et al., 2007](#); [Davidson et al., 2006](#)), we confirmed that this  
144 perturbation altered neither initial TVC induction, nor the expression of the *Foxf* driver  
145 (Figure S2). Consistent with proper TVC induction, *Foxf>dnFGFR* prevented neither  
146 TVC migration nor asymmetric divisions, but it abolished the expression of both

147 *Tbx1/10* in the STVCs and *Ebf* in the ASMFs (Figure 1C). This data indicate that FGF-  
148 MAPK signaling is required in the cardiopharyngeal progenitors and/or their progeny  
149 for ASM fate specification, beyond the initial TVC induction.

150 Upon FGF-MAPK-dependent induction, the TVCs express *Hand-related/Hand-r*  
151 (renamed after *Notrlc/Hand-like*; ([Christiaen et al., 2008](#); [Davidson and Levine, 2003](#);  
152 [Davidson et al., 2006](#); [Satou et al., 2004](#); [Stolfi et al., 2014c](#); [Woznica et al., 2012](#))),  
153 which encodes a basic helix-loop-helix (bHLH) transcription factor necessary for *Ebf*  
154 expression in the ASMFs (Razy-Krajka et al, 2014). Moreover, the *Hand-r* TVC  
155 enhancer contains putative Ets1/2 binding sites, which are necessary for reporter gene  
156 expression, and presumably mediate the transcriptional inputs of FGF-MAPK ([Woznica](#)  
157 [et al., 2012](#)). Since *Hand-r* and *Foxf* expressions start at approximately the same time in  
158 newborn TVCs, we used *Foxf>dnFGFR*, which did not alter the onset of *Hand-r*  
159 expression in the TVCs (Figure S2), to test whether the maintenance of *Hand-r*  
160 expression in migratory TVCs requires prolonged FGF-MAPK inputs. *Foxf>dnFGFR*  
161 inhibited *Hand-r* expression in late TVCs (Figure 1C), indicating that sustained *Hand-r*  
162 expression requires continuous FGF-MAPK signaling, as did TVC-expressed FGF-  
163 MAPK pathway components (Figure S2).

164 To test whether the spatial restriction of MAPK activity explains the patterned  
165 expressions of *Hand-r*, *Tbx1/10* and *Ebf* following asymmetric cell divisions, we used  
166 gain-of-function perturbations to force FGF-MAPK activity throughout the  
167 cardiopharyngeal mesoderm and assayed gene expression (Figure 2). We focused on the  
168 canonical FGF-MAPK pathway where signal transduction involves Ras, Raf, MEK and  
169 ERK downstream of FGFR and upstream of transcriptional effectors ([Lemmon and](#)  
170 [Schlessinger, 2010](#)). We first used M-Ras<sup>G22V</sup>, a defined constitutively active form of M-  
171 Ras, which mediates FGF signaling in *Ciona*, where other classical *Ras* genes are  
172 missing ([Keduka et al., 2009](#)), and focused on *Htr7* and *Tbx1/10* expression following



173 the first asymmetric TVC division in 15 hours post-fertilization (hpf) embryos. *Htr7*  
174 encodes a *trans*-membrane G-protein coupled receptor and, like *Hand-r*, its expression  
175 and maintenance in the TVCs require MAPK activity (Figure S2; ([Razy-Krajka et al.,](#)  
176 [2014](#))), and become restricted to the lateral STVC following asymmetric division.  
177 However, *Htr7* mRNAs are cleared more rapidly from the FHPs, making the patterned  
178 expression easier to analyze than that of *Hand-r* (Figures 2 and 3D; ([Razy-Krajka et al.,](#)  
179 [2014](#))). Importantly, misexpression of M-Ras<sup>G22V</sup> using the TVC-specific *Foxf* enhancer  
180 altered cell division asymmetry and/or orientation in under 50% of the embryos, still  
181 allowing us to identify large lateral and small median cells in a small majority of  
182 embryos (Figure S3). Compared to control embryos overexpressing wild-type M-Ras  
183 (M-Ras<sup>WT</sup>), TVC-specific gain of M-Ras function caused both persistent *Htr7* expression  
184 and ectopic activation of *Tbx1/10* in the small median cells following asymmetric  
185 divisions (Figure 2B,C). Similarly, *Foxf>M-Ras<sup>G22V</sup>*-expressing 18hpf larvae displayed  
186 ectopic *Ebf* activation throughout the cardiopharyngeal mesoderm (Figure 2B,C). This  
187 cannot be simply accounted for by general disruption of cell division patterns at this  
188 later stage (Figure S3), since similar disruptions can be caused by *Foxf>dnFGFR*, which  
189 inhibits *Ebf* expression (Figure 1C). These results indicated that forced M-Ras activity is  
190 sufficient to upregulate STVC and ASMF markers ectopically. This is consistent with the  
191 idea that spatially defined signaling upstream of M-Ras restricts MAPK activity, thus  
192 localizing STVC- and ASM-specific gene activities.

193 To further probe the signal transduction pathway, we engineered a constitutively  
194 active version of the Ciona Mek1/2 protein by introducing phosphomimetic mutations  
195 of two conserved serine residues in the catalytic domain, as previously shown for the  
196 mammalian homolog ([Cowley et al., 1994](#); [Mansour et al., 1994](#)). Early misexpression of  
197 Mek<sup>S220E,S216D</sup> in the B7.5 lineage using the *Mesp* enhancer caused ectopic TVC  
198 induction, mimicking the effects of gain of *Ets1/2* function (Figure S4; ([Davidson et al.,](#)

199 [2006](#)). As seen with M-Ras<sup>G22V</sup>, TVC-specific misexpression of Mek<sup>S220E,S216D</sup> using the  
200 *Foxf* enhancer also caused ectopic expression of *Htr7* and *Tbx1/10*, and *Ebf* in 15 and  
201 18hpf larvae, respectively (Figure 2B, C). Taken together, these results indicate that  
202 activity of the canonical FGF-Ras-MEK-ERK pathway is progressively restricted to the  
203 STVC and ASMF, and is both necessary and sufficient to promote STVC- and ASMF-  
204 specific gene expressions.

205

206 **Continuous FGF-MAPK activity is required for the successive activations of**  
207 ***Tbx1/10* and *Ebf*.**

208 FGF-MAPK signaling is sufficient and necessary to maintain *Hand-r* expression in  
209 late TVCs (Figure 1), and *Hand-r* is necessary for *Ebf* expression in the ASMF ([Razy-  
210 Krajka et al., 2014](#)). Therefore, it is possible that later FGF-MAPK signaling is  
211 dispensable for *Tbx1/10* and *Ebf* activation and ASM specification, as long as STVC and  
212 ASMF cells inherit sustained levels of *Hand-r* mRNAs and/or proteins. To disentangle  
213 late from early requirements of FGF-MAPK signaling, we incubated embryos at  
214 different stages with the MEK/MAPKK inhibitor U0126, which abolishes dual ERK  
215 phosphorylation and the initial MAPK-dependent TVC induction in *Ciona* embryos  
216 (Figure S1; ([Davidson et al., 2006](#); [Hudson et al., 2003](#))). MEK inhibition during TVC  
217 migration (i.e. between 9.5 and 12.5 hpf, Figure 3A) blocked the expression of *Hand-r*  
218 and *Htr7* in late TVCs (Figure 3B, E). U0126 treatments in late TVCs, and through the  
219 first asymmetric division (i.e. between 12 and 15 hpf, Figure 3A) did not alter TVC  
220 division patterns (Figure S3C), but it blocked both the maintenance of *Hand-r* and  
221 *Htr7*, and the activation of *Tbx1/10* in the STVCs (Figure 3C, D, F, G). Finally, MEK  
222 inhibition in late STVCs and through asymmetric divisions (i.e. between 15 and 18 hpf)  
223 also did not alter STVC divisions (Figure S3G), but it blocked the ASMF-specific  
224 expression of *Ebf* (Figure 3H). These results indicate that continuous MEK activity is

225 required throughout cardiopharyngeal development to successively activate TVC-,  
226 STVC-, and ASMF-expressed genes.

227 Since *Ebf* expression is maintained for several days in the ASMF derivatives as they  
228 differentiate into body wall and siphon muscles ([Razy-Krajka et al., 2014](#)), we tested  
229 whether continued MEK activity is also required for the maintenance of *Ebf* expression  
230 past its onset and cells' commitment to an ASM fate. Using both regular and intron-  
231 specific antisense probes, which specifically detect nascent transcripts ([Wang et al.,](#)  
232 [2013](#)), we showed that later MEK inhibition (i.e. U0126 incubation between 17 and 20  
233 hpf) did not block the maintenance of *Ebf* transcription in the ASMPs (Figure 3I, J).  
234 This indicates that sustained MEK activity is required until the onset of *Ebf* expression,  
235 but not beyond, and the maintenance of *Ebf* expression during ASM development is  
236 independent of MAPK.

237

238 Since U0126 treatments affect the whole embryo, we sought to further confirm the  
239 later roles for FGF-MAPK signaling specifically in the cardiopharyngeal mesoderm. To  
240 this aim, we used an STVC-specific enhancer from the *Tbx1/10* locus (termed *T6*; Figure  
241 3K, L; Figure S5; ([Tolkin and Christiaen, 2016](#)); Racioppi et al., in preparation) to drive  
242 expression of either dnFGFR or the constitutively active M-Ras<sup>G22V</sup> starting at ~14hpf,  
243 and assayed *Ebf* expression at 18hpf (Figure 3K, L). These perturbations minimally  
244 affected the cell division patterns (Figure S3), such that cells corresponding to FHP,  
245 SHP and ASMF could be identified by their position relative to the midline in many  
246 embryos (Figure 3K). M-Ras<sup>G22V</sup> misexpression caused conspicuous ectopic *Ebf*  
247 expression in the SHPs, whereas dnFGFR-mediated inhibition of MAPK activity blocked  
248 *Ebf* activation in the lateral ASMFs. These results support the notion that localized FGF-  
249 MAPK activity is necessary and sufficient for ASMF-specific expression of *Ebf*.

250

251 **Coherent feed-forward circuits for cardiopharyngeal mesoderm patterning**  
252 **and ASM fate specification.**

253 The above results indicate that *Hand-r*, *Tbx1/10* and *Ebf* require ongoing FGF-  
254 MAPK activity for their successive activations in the TVCs, STVCs and ASMFs,  
255 respectively. We previously showed that RNAi and/or CRISPR-mediated inhibition of  
256 either *Hand-r* or *Tbx1/10* function blocks *Ebf* activation in the ASMFs, where both  
257 *Hand-r* and *Tbx1/10* expressions are maintained ([Razy-Krajka et al., 2014](#); [Tolkin and](#)  
258 [Christiaen, 2016](#); [Wang et al., 2013](#)). We used epistasis assays to systematically test  
259 whether early regulators mediate the effects of FGF-MAPK on later gene expression and  
260 ASM fate specification, or whether FGF-MAPK signaling acts both upstream and in  
261 parallel to early regulators in a more complex regulatory circuit.

262 We first revisited the regulatory relationships between FGF-MAPK, *Hand-r* and  
263 *Tbx1/10* in late TVCs and early STVCs. We validated single guide RNAs (sgRNAs) for  
264 CRISPR/Cas9-mediated mutagenesis of *Hand-r* (Table S1; ([Gandhi et al., 2017a](#))), and  
265 determined that *Hand-r* function is necessary for *Tbx1/10* activation in the STVCs  
266 (Figure 4A). Co-expression of a CRISPR-resistant *Hand-r* cDNA (*Hand-r*<sup>PAMmis</sup>) rescued  
267 *Tbx1/10* expression in the STVCs, indicating that *Tbx1/10* down-regulation in this  
268 CRISPR "background" is specifically due to *Hand-r* loss-of-function (Figure 4A). To  
269 further probe if *Hand-r* activity is necessary for FGF-MAPK-dependent *Tbx1/10*  
270 expression, we used gain of M-Ras function in a *Hand-r* CRISPR "background".  
271 Whereas, misexpression of the constitutively active M-Ras<sup>G22V</sup> caused ectopic *Tbx1/10*  
272 expression, concomitant loss of *Hand-r* function diminished both endogenous and  
273 ectopic *Tbx1/10* expression in the STVC and FHP, respectively (Figure 4A). Although,  
274 remaining ectopic activation could still be observed, possibly because M-Ras<sup>G22V</sup> could  
275 boost *Hand-r* expression in heterozygous cells where CRISPR/Cas9 disrupted only one

276 copy of the gene. This data indicate that Hand-r function is necessary for FGF-MAPK-  
277 induced activation of *Tbx1/10*.

278 To further probe the epistatic relationships between *Hand-r* and MAPK signaling  
279 upstream of *Tbx1/10*, we attempted to rescue *Tbx1/10* expression in U0126-treated  
280 embryos, by over-expressing *Hand-r* with the TVC-specific *Foxf* enhancer. Neither did  
281 Hand-r over-expression cause ectopic *Tbx1/10* activation (in the FHPs), nor was it  
282 sufficient to rescue *Tbx1/10* expression in 15hpf STVCs (Figure 4B). Taken together,  
283 these data indicate that both Hand-r and MAPK activities are required to activate  
284 *Tbx1/10* in the STVCs. These results also imply that MAPK signaling is restricted to the  
285 STVC independently of Hand-r activity, which suffice to explain the STVC-specific  
286 activation of *Tbx1/10*. Finally, we isolated a minimal STVC-specific enhancer from the  
287 *Tbx1/10* locus and identified conserved putative Ets binding sites, which were necessary  
288 for reporter gene expression (Figure S5). This suggests that the FGF-MAPK-Ets  
289 pathway directly regulates *Tbx1/10* expression in the STVCs.

290

291 Next, we investigated the epistatic relationship between FGF-MAPK, *Hand-r*, and  
292 *Tbx1/10* upstream of *Ebf* in the ASMFs. We first used previously validated  
293 CRISPR/Cas9 reagents targeting the *Tbx1/10* coding region ([Tolkin and Christiaen,](#)  
294 [2016](#)), to confirm that B7.5-lineage-specific loss of *Tbx1/10* function inhibited *Ebf*  
295 activation, and verified that this effect could be rescued by over-expression of a  
296 CRISPR/Cas9-resistant *Tbx1/10* cDNA, expressed with a minimal TVC-specific *Foxf*  
297 enhancer (Figure 4C; *Tbx1/10*<sup>PAM<sub>mis</sub></sup>). In these rescue experiments, we observed ectopic  
298 *Ebf* activation in the SHP, as previously described when driving *Tbx1/10* expression  
299 with a TVC-specific *Foxf* enhancer ([Wang et al., 2013](#)). As explained below, this ectopic  
300 activation could be attributed to a precocious expression of *Ebf* in the STVCs (Figure  
301 4E). To test whether *Tbx1/10* was also required for ectopic *Ebf* expression in response to

302 MAPK activation (see Figure 2), we combined CRISPR/Cas9-mediated *Tbx1/10*  
303 knockout with constitutive MAPK activation using the M-Ras<sup>G22V</sup> mutant and observed  
304 a significant inhibition of both endogenous and ectopic *Ebf* expression in the 18hpf  
305 ASMF and SHP, respectively (Figure 4C). Taken together, these results show that  
306 *Tbx1/10* function is necessary for FGF-MAPK-induced expression of *Ebf* in the ASMFs.

307 To further test whether *Tbx1/10* acts in parallel and/or downstream of MAPK to  
308 activate *Ebf*, we combined gain of *Tbx1/10* function with perturbations of FGF-MAPK  
309 signaling and assayed *Ebf* expression. We realized that *Foxf*-driven misexpression of  
310 *Tbx1/10* caused precocious *Ebf* activation in 15hpf STVCs (Figure 4D, E). This  
311 precocious expression remained remarkably patterned, suggesting that STVC-restricted  
312 FGF-MAPK activity prevented *Ebf* expression in the dpERK-negative, small median  
313 FHPs (Figures 1B, 4E, S1). Indeed, co-expression of *Tbx1/10* and M-Ras<sup>G22V</sup> caused both  
314 precocious and ectopic *Ebf* expression in the 15hpf medial and lateral TVC derivatives,  
315 which would be FHPs and STVCs in control embryos, respectively. This data confirms  
316 that *Tbx1/10* misexpression does not suffice to cause ectopic *Ebf* expression in the  
317 FHPs, because the latter presumably lack FGF-MAPK activity, as is the case in control  
318 embryos.

319 U0126-mediated MEK inhibition from 12 to 15hpf, i.e. after the onset of  
320 *Foxf>Tbx1/10* misexpression, further confirmed that MAPK activity is required in  
321 parallel to *Tbx1/10* for precocious *Ebf* activation in 15hpf STVCs (Figure 4D, E). Taken  
322 together, these results indicate that *Tbx1/10* and MAPK are both required to activate  
323 *Ebf* in the cell cycle following that of *Tbx1/10* onset.

324

325 Since *Hand-r* expression is maintained in the ASMF, and CRISPR/Cas9- or RNAi-  
326 mediated *Hand-r* knockdown blocked both *Tbx1/10* (Figure 4A) and *Ebf* expression  
327 ([Razy-Krajka et al., 2014](#)), we reasoned that *Hand-r* could also act both upstream and in

328 parallel to *Tbx1/10* for *Ebf* activation. To test this possibility, we assayed *Ebf* expression  
329 in 18hpf ASMF following defined perturbations of *Hand-r* and *Tbx1/10*. As expected,  
330 CRISPR/Cas9-mediated *Hand-r* mutagenesis strongly inhibited *Ebf* expression, and  
331 this effect could be rescued by a CRISPR-resistant *Hand-r* cDNA (Figure 4F). To test  
332 whether this effect was mediated by a loss of *Tbx1/10* expression, we attempted to  
333 rescue the *Hand-r* loss-of-function by over-expressing *Tbx1/10* using the *Foxf* enhancer.  
334 As explained above, *Foxf*-mediated *Tbx1/10* misexpression caused precocious and  
335 ectopic *Ebf* expression in larvae co-electroporated with control sgRNAs (Figure 4D, E,  
336 F). By contrast, combining loss of *Hand-r* function with *Tbx1/10* misexpression  
337 inhibited both the endogenous and ectopic *Ebf* expression (Figure 4F), indicating that  
338 *Hand-r* is also required in parallel to *Tbx1/10* for *Ebf* activation in the ASMFs.

339 Taken together, these analyses suggest that coherent feed-forward circuits govern  
340 the sequential activation of *Hand-r*, *Tbx1/10* and *Ebf* in response to continuous but  
341 progressively restricted FGF-MAPK inputs (Figure 4G), thus linking spatial patterning  
342 to the temporal deployment of the regulatory cascade leading to localized *Ebf* activation  
343 and pharyngeal muscle specification.

344

### 345 **The cell cycle entrains the temporal deployment of the cardiopharyngeal** 346 **gene regulatory network.**

347 In principle, the feed-forward circuit described above is sufficient to explain the  
348 successive activations of *Hand-r*, *Tbx1/10* and *Ebf*. However, *Tbx1/10* and *Ebf* do not  
349 turn on until after TVC and STVC divisions, respectively. Notably, even when we  
350 misexpressed *Tbx1/10* in the TVCs, *Ebf* was activated only after cell division and in the  
351 lateral-most cells, where FGF-MAPK signaling is normally maintained (Figures 1B, 4E).  
352 This sequence of events -divisions followed by gene activation- is paramount as it  
353 permits the birth of first and second heart precursors, whose fates are antagonized by

354 *Tbx1/10* and *Ebf* ([Razy-Krajka et al., 2014](#); [Stolfi et al., 2010](#); [Wang et al., 2013](#)).  
355 Therefore, we sought to investigate the role(s) of the cell cycle in controlling the timing  
356 of *Tbx1/10* and *Ebf* activation.

357 We first evaluated the effects of cytochalasin B, a classic inhibitor of cytokinesis  
358 widely used to study cell fate specification in ascidians (Figure 5A; ([Whittaker, 1973](#))).  
359 Treatments starting before TVC divisions (12 hpf) did not block *Tbx1/10* or *Ebf*  
360 expression in embryos fixed after their normal onset at either 16 or 19hpf, respectively  
361 (Figure 5B). Similarly, treatment starting between the first and second asymmetric  
362 divisions (15hpf) did not block localized *Ebf* expression at 19hpf (Figure 5B). This  
363 indicates that *Tbx1/10* and *Ebf* activations occur by default in the absence of  
364 cytokinesis, most likely because FGF-MAPK signaling persists throughout the shared  
365 cytoplasm. This data thus illustrates how the spatial restriction of FGF-MAPK signaling,  
366 following cell divisions, leads to the localized activations of *Tbx1/10* and *Ebf*.

367 Cytochalasin treatments usually lead to the formation of polynucleated cells (e.g.  
368 Figure 5B, middle panel), because the cell cycle and nucleokinesis continue. To alter cell  
369 cycle progression more comprehensively, and specifically in the cardiopharyngeal  
370 lineage, we used genetically encoded inhibitors of cell cycle transitions: *Cdkn1b.a* and  
371 *Cdkn1b.b* (also known as *Noto16*), the ortholog of which is a potent inhibitor of the G1/S  
372 transition in the ascidian species *Halocynthia roretzi* ([Kuwajima et al., 2014](#)), and the  
373 G2/M inhibitor *Wee1* ([Dumollard et al., 2017](#)). We used the TVC-specific *Foxf* enhancer  
374 to misexpress these negative regulators of cell cycle progression, monitored cell  
375 divisions and assayed *Tbx1/10* expression at 15hpf, when control TVCs have divided and  
376 the lateral-most STVCs normally express *Tbx1/10*. Each perturbation efficiently  
377 inhibited TVC divisions, such that only two cells were visible on either side of the  
378 embryos (Figure 5D). In these delayed TVCs, *Tbx1/10* expression was strongly reduced  
379 compared to control STVCs (Figure 5D). However, 20 to 40% of the delayed TVCs



380 expressed *Tbx1/10* to variable extents. This suggests that the cardiopharyngeal  
381 regulatory network can qualitatively unfold independently of cell cycle progression, but  
382 the latter is necessary for *Tbx1/10* expression to its wild-type levels.

383 We next used the STVC-specific *Tbx1/10 T6* enhancer (Figure S5), to misexpress  
384 *Cdkn1b.a*, *Noto16* and *Wee1*, and assayed *Ebf* expression at later stages. Inhibitors of  
385 the G<sub>1</sub>/S transition failed to block STVC divisions (data not shown), most likely because  
386 *Tbx1/10(T6)*-driven products did not accumulate quickly enough to interfere with the  
387 G<sub>1</sub>/S transition in STVCs, since this cell cycle lasts only ~2 hours compared to ~6 hours  
388 for the TVC interphase. Therefore, we focused the analyses of *Ebf* response to cell cycle  
389 perturbations on misexpression of the G<sub>2</sub>/M inhibitor *Wee1*. Analyses of 18hpf larvae,  
390 fixed approximately 2 hours after the documented onset of *Ebf* expression in ASMFs  
391 ([Razy-Krajka et al., 2014](#)), indicated that *Ebf* can turn on in arrested STVCs that failed  
392 to divide upon *Wee1* misexpression (Figure 5E).

393 Because ~30% of the embryos showed variable expression, as was the case for  
394 *Tbx1/10* in the previous experiment, we reasoned that perturbations of the G<sub>2</sub>/M  
395 transition could alter the dynamics of *Ebf* upregulation. We investigated this possibility  
396 using embryos fixed every 30 minutes between 15.5hpf and 18hpf, when cells transition  
397 from a late *Tbx1/10+*; *Ebf-* STVC state to a committed *Ebf+*, *Mrf+* ASMF state ([Razy-  
398 Krajka et al., 2014](#); [Wang et al., 2013](#)). First, we scored the proportion of embryos with  
399 delayed STVCs or conspicuous ASMFs at each time point and showed that *Wee1*  
400 misexpression strongly delays cell cycle progression, blocking cell divisions in a  
401 substantial fraction of embryos (Figure S6).

402 The proportion of *Ebf+* ASMFs in control embryos progressively increased from  
403 ~20% at 15.5hpf to >90% by 18hpf, revealing an under-appreciated dynamic at the  
404 onset of *Ebf* expression, which appears to take at least one hour to be "strongly"  
405 expressed in >75% of newborn ASMFs (Figure S6).

406 To evaluate the impact of Wee1-induced mitosis inhibition on *Ebf* accumulation, we  
407 focused on undivided STVCs at each time point (hence the lower numbers in Figure S6A  
408 compare to Figure S6B). By 17hpf, *wee1*-expressing delayed STVCs showed "strong" *Ebf*  
409 expression in comparably high proportions of embryos. However, these proportions  
410 were significantly lower at 16 and 16.5hpf (Chi-square tests,  $P=0.002$  and  $P=0.0003$ ,  
411 respectively), with  $\sim 1.5$  and  $\sim 1.2$  times less "strongly" expressing cells than in the  
412 control distributions (hypergeometric tests,  $P=0.0005$  and  $P=0.0001$ , respectively).  
413 These semi-quantitative analyses suggest that the cardiopharyngeal network can  
414 eventually unfold independently of cell divisions, leading to high levels of *Ebf*  
415 expression, albeit with a delay. This suggests that STVC division entrains *Ebf*  
416 upregulation in early ASMFs.

417 Finally, we reasoned that Wee1-expressed delayed STVC that activate *Ebf* would not  
418 turn on heart markers ([Wang et al., 2017](#)). Indeed, delayed STVCs failed to activate the  
419 pan-cardiac *Lrp4/8*, and the SHP-markers *Kirrr* and *Dach* (Figure 5F; [Wang et al.,](#)  
420 [2017](#)). This indicated that coupling STVC division with localized FGF-MAPK activity  
421 and timed *Ebf* upregulation permits the localized activation of *Ebf* and the emergence of  
422 cardiac progenitors.

423

#### 424 **Transition from a MAPK-dependent to a MAPK-independent and** 425 **autoregulative mode of *Ebf* expression in early ASMFs.**

426 We sought to further probe the mechanisms that regulate the initiation of *Ebf*  
427 expression in early ASMFs, and their biological significance for fate specification. Since  
428 we observed a progressive accumulation of *Ebf* mRNAs, and a transition from a MAPK-  
429 dependent onset to a MAPK-independent maintenance of *Ebf* transcription (Figure 3I,  
430 J), we reasoned that the window of MAPK-dependence might coincide with the  
431 accumulation of *Ebf* mRNAs between 16 and 17hpf. To test this possibility, we treated

432 embryos with the MEK inhibitor U0126 at successive time points, assayed ongoing  
433 transcription using intronic probes and counted the numbers of *Ebf* transcribing cells  
434 (Figure 6A). This analysis revealed that *Ebf* transcription gradually lost its sensitivity to  
435 MAPK inhibition between 16 and 17hpf, i.e. during the first hour of the ASMF cycle  
436 when *Ebf* mRNAs normally accumulate (Figure S6A,B).

437       Because *Ebf* transcription becomes independent from MAPK by the time *Ebf* mRNA  
438 have accumulated to "high" levels, and because *Ebf* expression lasts for several days in  
439 the progeny of the ASMFs, we reasoned that autoregulation might suffice to maintain  
440 high levels of *Ebf* mRNA past the MAPK-dependent onset. To test this possibility, we  
441 misexpressed the *Ebf* coding sequence using the STVC-specific *T6* enhancer as  
442 described ([Tolkin and Christiaen, 2016](#)). Assaying endogenous *Ebf* transcription with  
443 intronic probes demonstrated that, in addition to its normal expression in the ASMFs,  
444 *Ebf* misexpression caused precocious and ectopic activation of the endogenous locus in  
445 the STVCs, and in the MAPK-negative SHPs, respectively (Figure 6C-F). This result  
446 suggests that *Ebf* transcription bypasses both requirements for cell-division coupling  
447 and MAPK inputs if high levels of *Ebf* gene products are present in the cell.

448       We reasoned that, if high levels of *Ebf* expression can promote its own transcription  
449 independently of MAPK signaling, then *Ebf* misexpression should be sufficient to rescue  
450 a chemical inhibition of MAPK at a critical stage. We tested this possibility by  
451 combining *Ebf* misexpression using the STVC-specific *T6* enhancer and U0126  
452 treatments starting at 16hpf, which normally block *Ebf* expression (Figure 6A, D-F). We  
453 observed that transcription of the endogenous *Ebf* locus became independent of early  
454 MAPK activity upon misexpression of an *Ebf* cDNA, further supporting the notion that  
455 high levels of *Ebf* expression suffice to maintain *Ebf* transcription independently of  
456 MAPK activity.

457

458 A potentially important implication of this transient MAPK requirement is to render  
459 *Ebf* expression initially reversible. For instance, *Ebf* occasionally turns on precociously  
460 in the STVCs of a small proportion of embryos (Figure S6C). Given the powerful anti-  
461 cardiogenic effects of Ebf ([Razy-Krajka et al., 2014](#); [Stolfi et al., 2010](#)), persistent *Ebf*  
462 expression would have dramatic consequences for SHP development ([Wang et al.,](#)  
463 [2013](#)). However, because MAPK activity is excluded from the SHPs, and the early phase  
464 of *Ebf* expression depends upon continuous MAPK activity, we surmise that *Ebf* cannot  
465 be maintained in the SHPs. For instance, when embryos from the same electroporated  
466 batch were fixed at the time of early U0126 treatment (i.e. 15.75 and 16.25hpf) and ~4  
467 hours later, at 20hpf, and assayed for *Ebf* transcription using intronic probes, initially  
468 wild-type patterns of *Ebf* transcription could not be maintained (Figure S7A). This  
469 suggests that, although *Ebf* can be activated precociously in a MAPK-dependent  
470 manner, its expression shuts off in the SHPs upon MAPK inhibition following STVC  
471 division.

472 We further addressed the interplay between cell division, MAPK signaling and *Ebf*  
473 expression. We reasoned that, if cell divisions entrain Ebf accumulation and the  
474 transition to a MAPK-independent autoregulative mode, then delaying STVC divisions  
475 should extend the period of MAPK-dependent *Ebf* transcription. We tested this  
476 possibility by expressing *Wee1* under the control of the STVC-specific *T6* enhancer, and  
477 treated embryos with U0126 at 17hpf, which inhibited the maintenance of *Ebf*  
478 transcription in only 15% to 20% of the control embryos (Figures 6A, S7B). The  
479 proportion of embryos showing U0126-sensitive *Ebf* transcription increased to almost  
480 50% upon *T12>Wee1* expression (Figure S7B), which is consistent with our hypothesis  
481 that inhibiting the G2/M transition delays the accumulation of *Ebf* gene products, thus  
482 postponing the transition from a low level/MAPK-dependent to an high level/MAPK-  
483 independent and self-activating mode of *Ebf* regulation.

484        We propose a model for *Ebf* regulation whereby Hand-r, Tbx1/10, ongoing MAPK  
485 signaling and cell-cycle-regulated transcriptional input(s) govern the onset and initial  
486 accumulation of *Ebf* gene products during the first hour of the ASMF cycle, whereas the  
487 maintenance of *Ebf* expression relies primarily on MAPK-independent autoactivation,  
488 following initial accumulation (Figure 7).

## 489 **Discussion**

490 Here, we demonstrated that the progressive restriction of FGF-MAPK signaling  
491 follows oriented and asymmetric cell divisions of multipotent progenitors and patterns  
492 the ascidian cardiopharyngeal mesoderm in space and time. Dynamic FGF-MAPK  
493 activity patterns lead to the localized expression of *Hand-r*, *Tbx1/10* and *Ebf* in fate-  
494 restricted pharyngeal muscle precursors, and their concomitant exclusion for first and  
495 second heart precursors. We show that coherent feedforward circuits encode the  
496 successive activations of *Hand-r*, *Tbx1/10* and *Ebf*, whereas cell divisions entrain the  
497 progression of this regulatory sequence and thus define the timing of gene expression.  
498 Finally, we provide evidence that the initiation of *Ebf* expression depends on MAPK  
499 activity in early ASMF, until *Ebf* accumulation permits MAPK-independent auto-  
500 activation. Given the potent anti-cardiogenic, and pro-pharyngeal muscle effects of *Ebf*  
501 ([Razy-Krajka et al., 2014](#); [Stolfi et al., 2010](#)), we surmise that the latter switch  
502 corresponds to the transition from a cardiopharyngeal multipotent state to a committed  
503 pharyngeal muscle identity.

504

### 505 **Spatial patterning by localized maintenance of FGF-MAPK signaling.**

506 Our results demonstrate that MAPK signaling is maintained only in the lateral-most  
507 daughter cells following each asymmetric division of multipotent cardiopharyngeal  
508 progenitors - the TVCs and STVCs. This asymmetric maintenance is necessary and  
509 sufficient for the progressive and localized deployment of the pharyngeal muscle  
510 network. Notably, the TVCs themselves are initially induced by similar polarized FGF-  
511 MAPK signaling coincidental to asymmetric cell divisions of their mother cells, the B8.9  
512 and B8.10 founder cells ([Davidson et al., 2006](#)). At this stage, asymmetrical  
513 maintenance of sustained FGF-MAPK signaling involves intrinsic Cdc42-dependent  
514 polarity of the founder cells, which promotes polarized cell-matrix adhesion of the

515 prospective TVC membrane to the ventral epidermis. The latter differential integrin-  
516 mediated adhesion promotes localized MAPK activation, leading to TVC induction  
517 ([Cooley et al., 2011](#); [Norton et al., 2013](#)). It has been proposed that adhesion- and  
518 caveolin-dependent polarized FGFR recycling during mitosis accounts for the localized  
519 activation of MAPK in the prospective TVCs ([Cota and Davidson, 2015](#)). Whereas  
520 similar mechanisms could in principle account for asymmetric maintenance of FGF-  
521 MAPK signaling in STVCs and ASMFs, this has not been formally tested and there are  
522 notable differences opening the possibility that other mechanisms may be at work:  
523 during TVC induction, MAPK signaling is maintained in the smaller daughter cell that  
524 contacts the epidermis, whereas in the following divisions, MAPK activity persists in the  
525 larger daughter cells and all cells maintain contact with the epidermis (Kaplan et al., in  
526 preparation). Moreover, using fusion proteins as in previous studies, we could not  
527 observed a marked polarized distribution of FGFR molecules to the lateral-most cells  
528 (the STVCs and ASMFs; Kaplan et al., in preparation). However, the fact that  
529 constitutively active forms of M-Ras and Mek1/2 were sufficient to bypass the loss of  
530 MAPK activity, and impose pharyngeal muscle specification, indicates that differential  
531 FGF-MAPK activity is regulated upstream of M-Ras. Further work is needed to  
532 elucidate the cellular and molecular mechanisms governing the spatiotemporal patterns  
533 of FGF-MAPK signaling in the cardiopharyngeal mesoderm. In particular, it will be  
534 important to disentangle the relative impacts of extrinsic (i.e. tissues, contacts) vs.  
535 intrinsic (i.e. asymmetric cell division) effects onto FGF-MAPK signaling and the  
536 downstream transcriptional inputs.

537 Our preliminary analyses indicate that perturbations of the FGF-Ras-MEK pathway  
538 can alter cardiopharyngeal cell division patterns (Figure S3). While these effects did not  
539 account for the observed changes in gene expression, future studies will unravel FGF-

540 MAPK-dependent and cardiopharyngeal-specific mechanisms governing the orientation  
541 and asymmetry of progenitor cell division (Kaplan et al., in preparation).

542

### 543 **Transcriptional consequences of differential FGF-MAPK signaling.**

544 Differential FGF-MAPK signaling rapidly impacts cell-specific gene expression, we  
545 thus surmise that transcriptional effectors are dynamically regulated. Even though we  
546 have not formally identified the downstream DNA-binding transcription factor (see  
547 discussion below), it is conceivable that the phosphorylated forms of either  
548 transcriptional effector could persist through cell division upon maintenance of FGF-  
549 MAPK activity. However, we have shown that continuous MAPK activity is needed  
550 following each division. Therefore, we must invoke elusive phosphatase activities, such  
551 as dual-specificity phosphatases (DUSPs; ([Patterson et al., 2009](#)), which would reset  
552 transcriptional effectors to a dephosphorylated state, thus rendering steady-state FGF-  
553 Ras-MAPK inputs necessary.

554 Systematic dephosphorylation of FGF-MAPK transcriptional effectors is particularly  
555 important for heart fate specification. As shown in our companion paper ([Wang et al.,  
556 2017](#)), whole genome analyses indicate that heart-specific *de novo* gene expression  
557 requires MAPK inhibition ([Wang et al., 2017](#)). The molecular mechanisms remain  
558 elusive, but one simple possibility is that, lest fate-restricted heart precursors inhibit  
559 MAPK activity, they will activate *Tbx1/10* and *Ebf*, which will block the cardiac program  
560 ([Razy-Krajka et al., 2014](#); [Stolfi et al., 2010](#); [Wang et al., 2013](#)).

561 Finally, we previously proposed that repressor inputs from Nk4/Nkx2-5 are needed  
562 in the second heart precursors to avoid ectopic activation of *Ebf* ([Wang et al., 2013](#)). The  
563 observation that *Nk4* transcripts are detected in all cardiopharyngeal cells opened the  
564 question as to how *Ebf* would escape repression by Nk4 in the ASMFs. Differential  
565 MAPK activity offers an intriguing possibility: for instance, Nk4/Nkx2.5-mediated



566 repression in other species involves the co-repressor Groucho/TLE ([Choi et al., 1999](#)),  
567 which is strongly expressed in the cardiopharyngeal mesoderm ([Razy-Krajka et al.,](#)  
568 [2014](#)); and, in flies, MAPK-mediated phosphorylation of Groucho inhibits its repressor  
569 function ([Cinnamon et al., 2008](#); [Cinnamon and Paroush, 2008](#); [Hasson et al., 2005](#)).  
570 Therefore, it is possible that persistent MAPK signaling dampens Groucho/TLE-  
571 mediated repressive inputs on cell-specific regulatory genes like *Ebf*. Future studies will  
572 determine whether such mechanisms provide bistable switches underlying MAPK-  
573 dependent fate choices in the cardiopharyngeal mesoderm.

574

### 575 **Temporal deployment of the pharyngeal muscle network**

576 The localized and successive activation of *Tbx1/10* and *Ebf* in STVCs, and ASMFs,  
577 respectively, are important features of the cardiopharyngeal network that permit the  
578 emergence of diverse cell fates: first and second heart precursors, and atrial siphon  
579 muscle precursors. Experimental misexpression of *Ebf* throughout the  
580 cardiopharyngeal mesoderm suffice to inhibit heart development ([Razy-Krajka et al.,](#)  
581 [2014](#); [Stolfi et al., 2010](#)), illustrating the importance of *Ebf* restriction to the ASMF for  
582 the emergence of first and second heart precursors.

583 Our analyses indicate that the sequential activations of *Hand-r*, *Tbx1/10* and *Ebf* is  
584 encoded in the feed-forward structure of this sub-circuit, whereas the continuous  
585 requirement for MAPK inputs and their progressive exclusion from heart progenitors  
586 restrict the competence to activate *Tbx1/10* and *Ebf* to the most lateral cells, after each  
587 division. Our model implies that each gene may directly respond to transcriptional  
588 inputs from MAPK signaling. We have not formally identified the transcription  
589 factors(s) that mediate the transcriptional response to FGF-MAPK signaling. However,  
590 multipotent cardiopharyngeal progenitors express *Ets1/2* and *Elk*, two common  
591 transcriptional effectors of FGF/MAPK signaling in *Ciona* ([Bertrand et al., 2003](#);

592 [Christiaen et al., 2008](#); [Davidson et al., 2006](#); [Gainous et al., 2015](#)), and Ets1/2 has been  
593 implicated in the initial FGF-MAPK-dependent induction of multipotent TVCs  
594 ([Christiaen et al., 2008](#); [Davidson et al., 2006](#)), and its expression is also progressively  
595 restricted to the lateral-most progenitors following each division ([Razy-Krajka et al.,](#)  
596 [2014](#)). Taken together, Ets1/2 and, to some extent, Elk are intriguing candidate  
597 transcriptional effectors of FGF/MAPK signaling in cardiopharyngeal development.

598 The binding preferences of Ets-family factors have been extensively studied in  
599 *Ciona*, and they do not depart markedly from conserved Ets-family binding sites with a  
600 GGAW core ([Bertrand et al., 2003](#); [Farley et al., 2015](#); [Farley et al., 2016](#); [Gueroult-](#)  
601 [Bellone et al., 2017](#); [Khoueiry et al., 2010](#)). Putative Ets-family binding sites in the TVC-  
602 specific *Hand-r* enhancer are conserved between *Ciona intestinalis* and its sibling  
603 species *C. robusta* and *C. savignyi*, and necessary for its activity in reporter assays  
604 ([Woznica et al., 2012](#)). Similarly, minimal STVC and ASM enhancers for *Tbx1/10* and  
605 *Ebf*, respectively, contain conserved putative Ets-family binding sites, which contribute  
606 to proper reporter gene expression in transfection assays (Figure S5; ([Razy-Krajka et al.,](#)  
607 [2014](#); [Wang et al., 2013](#)) and data not shown). Taken together, these observations  
608 suggest that the proposed feed-forward sub-circuit involves direct transcriptional inputs  
609 from FGF-MAPK-regulated Ets-family factors on the cardiopharyngeal enhancers of  
610 *Hand-r*, *Tbx1/10* and *Ebf*.

611

612 Whereas the regulatory architecture of the MAPK; *Hand-r*; *Tbx1/10*; *Ebf* sub-circuit  
613 explains the sequence of activation events, it is also crucial for its correct deployment,  
614 and the generation of diverse cell identities, that genes are not fully activated before  
615 successive cell divisions. While divisions are not absolutely required for *Ebf* to  
616 eventually turn on, cell cycle progression appears to entrain the deployment of this  
617 network, especially for *Tbx1/10* and *Ebf* activation in STVCs and ASMFs, respectively.

618 These observations imply that the intrinsic dynamic of the network is slower than  
619 observed. This allows first and second heart precursors to be born prior to the onset of  
620 *Tbx1/10* and *Ebf*, respectively. The latter sequence is essentially for the heart  
621 progenitors to escape the anti-cardiogenic effects of *Tbx1/10* ([Wang et al., 2013](#)), and  
622 *Ebf* ([Razy-Krajka et al., 2014](#)).

623 Initial *Ebf* expression in early ASMFs is also labile and MAPK-dependent for  
624 approximately one hour. This continued requirement for MAPK inputs ensures that, in  
625 the rare instances when *Ebf* expression starts in the multipotent STVC progenitors  
626 and/or expands to the nascent SHPs, inhibition of MAPK shuts off *Ebf* expression  
627 before it reaches the levels needed for commitment to an ASM fate. Indeed, our results  
628 indicate that, once *Ebf* mRNAs have accumulated to high levels, its expression becomes  
629 auto-regulative and MAPK-independent. We surmise that this transition coincides with  
630 a fundamental switch from a multipotent cardiopharyngeal state to a committed  
631 pharyngeal muscle identity.

632 From this standpoint, the observed entrainment of *Ebf* expression by the cell cycle  
633 can be seen as acceleration of the transition to commitment following asymmetric  
634 division of multipotent progenitors. Although the mechanisms remain elusive, it is  
635 likely that this requires the M/G1 transition, as the G1 phase has been shown to be  
636 particularly conducive to the expression of fate-specific regulators in mammalian  
637 pluripotent stem cells ([Dalton, 2015](#); [Pauklin et al., 2016](#); [Pauklin and Vallier, 2013](#);  
638 [Soufi and Dalton, 2016](#)).

639

## 640 **Conserved dual effects of FGF-MAPK signaling on heart development in** 641 **chordates**

642 Previous studies highlighted how FGF-MAPK signaling is necessary along side *Mesp*  
643 during early cardiac development in *Ciona* ([Christiaen et al., 2008](#); [Davidson, 2007](#);

644 [Davidson et al., 2006](#)), and how this early requirement also exists in vertebrates ([Abu-](#)  
645 [Issa et al., 2002](#); [Alsan and Schultheiss, 2002](#); [Barron et al., 2000](#); [Brand, 2003](#); [Reifers](#)  
646 [et al., 2000](#); [Zaffran and Frasch, 2002](#)). We now know that these early FGF-MAPK  
647 inputs induce and maintain multipotent cardiopharyngeal states in *Ciona*, including the  
648 *Tbx1/10+* multipotent progenitors that eventually produce the second heart lineage  
649 ([Razy-Krajka et al., 2014](#); [Stolfi et al., 2010](#); [Wang et al., 2013](#)), ([Wang et al., 2017](#)) and  
650 this study). Similarly, in vertebrates, regulatory interplay between Fgf8 and Fgf10  
651 signaling and Tbx1 is required for development of both pharyngeal arch and second  
652 heart field derivatives, presumably in part by maintaining an undifferentiated and  
653 proliferative state ([Abu-Issa et al., 2002](#); [Aggarwal et al., 2006](#); [Brown et al., 2004](#);  
654 [Chen et al., 2009](#); [Hu et al., 2004](#); [Ilgan et al., 2006](#); [Kelly and Papaioannou, 2007](#);  
655 [Park et al., 2006](#); [Park et al., 2008](#); [Vitelli et al., 2002b](#); [Watanabe et al., 2010](#);  
656 [Watanabe et al., 2012](#)). In fish, FGF signaling is necessary for cardiomyocyte addition at  
657 the arterial pole, in a manner reminiscent of its role in second heart field development  
658 ([de Pater et al., 2009](#); [Lazic and Scott, 2011](#)). Notably, FGF signaling acts in successive  
659 phases, and its inhibition is necessary for final myocardial specification and  
660 differentiation ([Hutson et al., 2010](#); [Marques et al., 2008](#); [Tirosh-Finkel et al., 2010](#);  
661 [van Wijk et al., 2009](#)). Conversely, continued FGF signaling beyond the multipotent  
662 mesodermal progenitor stages was shown to promote smooth muscle and epicardial  
663 differential in the heart ([Hutson et al., 2010](#); [van Wijk et al., 2009](#)), and also myoblast  
664 specification and/or skeletal muscle differentiation in the head, with the expression of  
665 FGF ligands being maintained in the pharyngeal arches ([Bothe et al., 2011](#); [Buckingham](#)  
666 [and Vincent, 2009](#); [Michailovici et al., 2015](#); [Michailovici et al., 2014](#); [von Scheven et](#)  
667 [al., 2006](#)). Taken together, these and our data suggest that FGF-MAPK signaling plays  
668 evolutionary conserved roles during chordate cardiopharyngeal development, by  
669 promoting the specification of successive mesodermal and *Tbx1+* multipotent states,

670 and a fate-restricted non-cardiac muscle identity, while MAPK inhibition is required for  
671 myocardial specification and differentiation in the first and second heart field,  
672 successively.

673 **Material and methods**

674 **Animals, electroporations, and chemical treatments**

675 Gravid wild *Ciona intestinalis* type A, now called *Ciona robusta* ([Pennati et al., 2015](#)),  
676 were obtained M-REP (Carlsbad, CA, USA), and kept under constant light to avoid  
677 spawning. Gametes from several animals were collected separately for *in vitro* cross-  
678 fertilization followed by dechoriation and electroporation as previously described  
679 ([Christiaen et al., 2009a, b](#)). Different quantities of plasmids were electroporated  
680 depending on the constructs. Typically, 50 µg of DNA was electroporated for NLS::lacZ  
681 or plain mCherry driving constructs but only 15 µg for *Mesp-1>H2B::mCherry*. For  
682 perturbation constructs, 70 µg were usually electroporated, except for  
683 *Mesp>NLS::Cas9::NLS* (30 µg) and pairs of U6>sgRNA plasmids (25 µg each). U0126  
684 (Cell Signaling Technology, Danvers, MA) was used at 5µM in artificial seawater from a  
685 stock solution of 20mM in DMSO. Cytochalasin B (Sigma, Saint Louis, MO) was used at  
686 ~3 µg/mL from a 10 mg/mL stock solution in DMSO as previously performed ([Jeffery et](#)  
687 [al., 2008](#)). Control embryos were incubated in parallel with corresponding  
688 concentrations of DMSO alone.

689

690 ***In situ* hybridization**

691 *In situ* hybridizations were carried out essentially as described previously ([Christiaen et](#)  
692 [al., 2009c](#); [Razy-Krajka et al., 2014](#)), using DIG labeled riboprobes, anti-DIG-POD Fab  
693 fragments (Roche, Indianapolis, IN), and Tyramide Amplification Signal coupled to  
694 Fluorescein (Perkin Elmer, MA). Reporters expressed in the lineage of interest were  
695 marked using anti-β-galactosidase monoclonal mouse antibody (1:1000; Promega,  
696 Fitchburg, WI) or anti-mCherry rabbit polyclonal antibody (1:500; BioVision 5993-  
697 100), respectively targeted with anti-mouse or anti-rabbit secondary antibody coupled  
698 with Alexa 648 (1:500; Invitrogen, Carlsbad, CA). The different probes used in this

699 study were described previously ([Razy-Krajka et al., 2014](#); [Stolfi et al., 2010](#); [Wang et](#)  
700 [al., 2013](#)).

701

### 702 **dpERK/mcherry double fluorescent immunostaining**

703 Samples were fixed, as for *in situ* hybridizations, in MEM-PFA with Tween 20 (0.05%)  
704 but only for 30 minutes at room temperature, washed three times in PBSt (Tween 20  
705 0.01%) for 10 minutes, gradually dehydrated every 10 minutes in Ethanol/PBS series  
706 (33%, 50%, 80%) and Methanol 100%. Samples were then gradually rehydrated every  
707 10 minutes in Methanol/PBSt series, rinsed three times in PBSt, permeabilized with  
708 PBS Triton-100 (0.2%) for 30 minutes and incubated for 2 hours at room temperature  
709 with anti-dpERK mouse monoclonal antibody (1:200; Sigma, Saint Louis, MO) and  
710 anti-mCherry polyclonal antibody from rabbit (1:500; Biovision, Milpitas, CA) in PBS  
711 0.01% Triton-100 (T-Pbs) supplemented with 2% normal goat serum. Samples were  
712 then washed three times in T-PBS and incubated in anti-mouse and anti-rabbit  
713 antibodies (1:500 each), respectively coupled with Alexa 488 and Alexa 568  
714 (Invitrogen, Carlsbad, CA), overnight at 4°C or for 2 hours at room temperature.  
715 Finally, samples were rinsed three times in T-PBS for 15 minutes and mounted in  
716 Prolong Gold (Molecular Probes, Eugene, OR).

717

### 718 **Molecular cloning**

719

720 Coding sequences for wild-type M-Ras (KH.L172.2), Mek1/2 (KH.L147.22), Cdkn1b.a  
721 (Cdkn1b, KH.C14.564), and Cdkn1b.b (Noto16, KH.S643.6) were PCR-amplified from  
722 cDNA libraries prepared by reverse transcription of total RNA from mixed  
723 developmental stages. Insertion of the products into expressing vectors was performed  
724 using regular restriction/ligation or In-fusion (Clontech, Mountain View, CA)  
725 procedure. Oligonucleotide directed mutagenesis or two-step overlap PCRs were used to

726 generate the point mutated forms M-Ras<sup>G22V</sup> and Mek<sup>S220E,S216D</sup> from the corresponding  
727 wild-type sequences. We also used oligonucleotide directed mutagenesis to generate  
728 mismatches in the PAM sequences adjacent to the sgRNA targets for Hand-r (153C>T  
729 574C>T for Hand-r<sup>PAMmis</sup>) and Tbx1/10 (325G>A and 579G>A for Tbx1/10<sup>PAMmis</sup>). Due to  
730 the absence of a correct PAM sequence (NGG, (reverse complement CCN)),  
731 overexpressed Hand-r<sup>PAMmis</sup> and Tbx1/10<sup>PAMmis</sup> are resistant to the Cas9 nuclease  
732 activity. We also used oligonucleotide directed mutagenesis to generate the mutations in  
733 two putative Ets binding sites from the corresponding wild-type sequence of the  
734 *Tbx1/10* enhancer element: -3646TC>CT -3638GA>AG upstream from the initiation  
735 codon (E1 and E2 in Figure S5 C, respectively). Primer sequences are listed in  
736 Supplementary Table 1.

737

738

### 739 **CRISPR/Cas9-mediated loss of Hand-r function**

740 The pair of single guide RNA (sgRNA) targeting Tbx1/10 (sgTbx1/10) has been validated  
741 previously ([Tolkin and Christiaen, 2016](#)). Rescue of the Tbx1/10 loss-of-function was  
742 achieved by TVC-specific overexpression of Tbx1/10<sup>PAMmis</sup> driven by a *Foxf* enhancer  
743 (*Foxf-1*>Tbx1/10<sup>PAMmis</sup>). For Hand-r loss of function, sgRNAs were first designed to  
744 avoid genomic off-targets and tested as described ([Gandhi et al., 2017b](#)). In short,  
745 sgRNA expressing cassettes (U6>sgRNA) were assembled by single step overlap PCR.  
746 Individual PCR products (~25 µg) were electroporated with EF1a>NLS::Cas9::NLS  
747 (30µg), Myod905>Venus (50 µg), driving ubiquitous expression of Cas9 and a widely  
748 expressed fluorescent reporter construct, respectively. Efficient electroporation was  
749 confirmed by observation of fluorescence before genomic DNA extraction around 16 hpf  
750 (18°C) using QIAamp DNA Micro kit (Qiagen, German Town, MD). Mutagenesis  
751 efficacy of individual sgRNAs, as a linear function of Cas9-induced indel frequency, was



752 estimated from electrophoregrams following Singer sequencing of the targeted regions  
753 amplified from extracted genomic DNA by PCR. Result of the relative quantification of  
754 the indel frequency (“corrected peakshift” of 22% and 24%) was considered high enough  
755 for both sgRNAs targeting Hand-r, which were finally selected. The corresponding  
756 cassettes were cloned into plasmid for repeated electroporations to study the loss of  
757 function of Hand-r. Rescue of Hand-r loss-of-function was achieved by overexpression  
758 of Hand-r<sup>PAMmis</sup> driven by a Foxf TVC specific enhancer (Foxf-1>Hand-r<sup>PAMmis</sup>). In order  
759 to control the specificity of the CRISPR/Cas9 system, sgRNAs targeting *Neurogenin*, a  
760 gene not expressed in the TVC and their progeny, was electroporated in parallel.  
761 Sequences of the DNA targets and oligonucleotides used for the sgRNAs are listed in  
762 Supplementary Table 1.

763

#### 764 ***Tbx1/10* enhancer and cis-regulatory analysis**

765 To isolate the minimal STVC-specific element of *Tbx1/10*, we used conserved non  
766 coding sequences between *Ciona robusta* and *Ciona savignyi* as a guide for molecular  
767 dissection (Figure S5 A, <http://genome.lbl.gov/vista/index.shtml>; (Frazer et al., 2004)).  
768 We cloned a full-length cis-regulatory DNA construct (~7kbp) that was analyzed by  
769 introducing large deletions to map the functional elements. We found a fragment of  
770 1264 bp, that we called T6, located at -4682 bp upstream from the initiation codon that  
771 was sufficient for STVC expression as well as in the mesenchyme and endoderm of the  
772 reporter gene (Figure S5 A, B). 5' deletions of the T6 element show that the main cis-  
773 regulatory elements required exclusively for STVC expression map in a 575 bp element,  
774 which we called T12, at -4116 bp upstream from the initiation codon sufficient (Figure  
775 S5A). The sequence of this element, which we called *T12*, reveals the presence of  
776 putative Ets1/2 binding sites (Figure S5C) that were predicted using JASPAR (Khan et  
777 [al., 2017](#)) and CisBP (Weirauch et al., 2014) databases. The minimal *Tbx1/10* STVC-

778 specific enhancer was further analyzed using point mutations of the candidate Ets1/2  
779 sites with higher predicted scores (Figure S5D).

780

### 781 **Observation and imaging**

782 Samples were usually scored under a DM2500 epifluorescent microscope (Leica  
783 Microsystems, Wetzlar, Germany). Imaging was performed using a TCS SP8 X inverted  
784 confocal microscope equipped with a white light laser, AOBS and HyD detectors (Leica  
785 Microsystems).

786


### 787 **Acknowledgement**

788 We thank Robert Kelly (Université Aix-Marseille, CNRS, France) for feedbacks on the  
789 manuscript. We are grateful to Alberto Stolfi for collaborative inputs throughout the  
790 project. We thank Farhana Salek and Kristyn Millan for technical support. This project  
791 was funded by NIH/NHLBI R01 award HL108643, and trans-Atlantic network of  
792 excellence award 15CVDO1 from the Leducq Foundation to L.C.

793

794 **Figures**

795



796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816


817

818

819

**Figure 1. Spatio-temporal restriction of ERK activity reflects FGF requirement for the specification of cardiopharyngeal progenitors.** (A) Schematic of *Ciona* development showing asymmetric cell divisions and resulting cell fates of the cardiopharyngeal mesoderm (CPM). Embryonic and larval stages (St) according to (Hotta et al., 2007) with hours post fertilization (hpf) at 18°C. Anterior tail muscle (ATM, gray), trunk ventral cell (TVC, green), secondary TVC (STVC, green), first heart precursor (FHP, red), second heart precursor (SHP, orange), atrial siphon founder cell (ASMf, blue). Black bars link sister cells. Dashed lines: ventral midline. The first stage presents a quasi-lateral view while the second and third stages present quasi-ventral views. Anterior is to the left. Scale bar, 50 µm. (B) ERK activity visualized by anti-dpERK antibody (green). TVCs and their progeny are marked by mCherry driven by *Mesp* and revealed by anti-mCherry antibody (red). *H2B::mCherry* and *hCD4::mCherry* accumulate in the nuclei and at the cell membrane, respectively. Arrowheads indicate STVCs and ASMfS at 14 and 16 hpf, respectively. Arrows indicate FHPs and open arrowheads mark SHPs. Anterior to the left. Scale bar, 10 µm. See also Figure S1 for broader time series of dpERK immunostaining in the B7.5 lineage. (C, D) TVC-specific overexpression of dnFGFR induces loss of expression of key lateral CPM markers visualized by *in situ* hybridization. (C) Representative expression patterns of key CPM genes (*Hand-related*, *Tbx1/10*, *Ebf*) in control embryos (Ctrl, electroporated with *Foxf(TVC):bpFOG-1>Venus*) and TVC-specific dnFGFR expression (electroporated with *Foxf(TVC):bpFOG-1>dnFGFR::mCherry*) individuals. TVCs and progeny are marked with *Mesp>NLS::lacZ* (red). Loss of expression in half of the TVC progeny, as presented for *Ebf*, is assumed to be due to left-right mosaicism. Arrowheads mark the ASMfS. Anterior is to the left. Scale bar, 10 µm. (D) Corresponding histograms with the phenotype proportions. For simplicity, loss of gene expression in half or all of the TVCs and their progeny were combined in the same category. "n" corresponds to the number of individual halves documented per condition.


820



821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837

**Figure 2. Constitutively active M-Ras and MEK are sufficient to impose a pharyngeal muscle fate in the cardiopharyngeal lineage.** (A) Diagram of the FGF/MAPK transduction pathway with constitutive activation by M-Ras<sup>G22V</sup> and MEK<sup>S216D,S220E</sup> mutants. (B) Expression patterns of markers of the lateral TVC progeny, *Htr7* (a, b, c), *Tbx1/10* (d, e, f) and *Ebf* (g, h, i), visualized by *in situ* hybridization following TVC-specific over-expression of M-Ras<sup>WT</sup> (as control), M-Ras<sup>G22V</sup> and MEK<sup>S216D,S220E</sup>. M-Ras<sup>WT</sup> overexpression (a, d, g) does not alter the wild-type spatial expression patterns of *Htr7*, *Tbx1/10* and *Ebf* in lateral TVC derivatives (STVC and ASMF) and excluded from the median heart precursors. TVC-specific over-expression of M-Ras<sup>G22V</sup> (b, e, h) or MEK<sup>S216D,S220E</sup> (c, f, i) induces ectopic expression of STVC and/or ASMF markers (*Htr7*, *Tbx1/10* and *Ebf*) in the more median cells, that normally form cardiac precursors. Arrowheads indicate STVCs and ASMFs at 15 and 18 hpf, respectively. Arrows indicate FHPs and open arrowheads mark SHPs. At 18 hpf, the FHPs start dividing or have divided into 4 cells. Anterior to the left. Scale bar, 10  $\mu$ m. (C) Corresponding histograms: Larvae with TVC-specific over-expression of MEK<sup>WT</sup> retain the wild-type expression patterns. For simplicity, ectopic expressions in half to all of the cardiac precursors were combined in the same phenotype category. "n" corresponds to the number of embryo halves documented per condition. See also Figure S2.

838




**Figure 3. Temporal requirement for MAPK activity permits the progressive deployment of the cardiopharyngeal regulatory program.** (A) Summary of the CPM cell lineage showing the different U0126 treatments with regard to the timing of the cell divisions. Abbreviations and color codes as in Figure 1. (B, C) Proportions of embryo halves with wild-type or downregulated expression of *Hand-r* at 12.5 hpf (B) and 15 hpf (C) following 3-hour incubations in U0126 (with DMSO as control treatment). (D) *Hand-r* expression visualized by *in situ* hybridization at 15 hpf in control (DMSO treated) and U0126 treated embryos. In control embryos, *Hand-r* remains expressed in the STVCs and downregulated in the FHPs. In U0126 (12-15 hpf) treated embryos, downregulation of *Hand-r* expression is observed throughout the TVC progeny (STVCs and FHPs), suggesting inhibition of transcription and inheritance of remnant

839  
840  
841  
842  
843  
844  
845  
846  
847  
848

849 transcripts following TVC divisions. **(E, F)** Proportions of embryo halves with wild-type or downregulated  
850 expression of *Htr7* at 12.5 hpf (E) and 15 hpf (F) following 3-hour incubations in U0126 (with DMSO as  
851 control treatment). **(G)** Proportions of larvae with wild-type expression or downregulated expression of  
852 *Tbx1/10* at 16 hpf following 4-hour incubation in U0126 (with DMSO as control). **(H)** Proportions of larvae  
853 with wild-type or downregulated expression of *Ebf* at 18 hpf following a three hour incubation in U0126  
854 (with DMSO as control). **(I)** Proportions of larvae with wild-type or downregulated transcription of *Ebf* at  
855 18 hpf following a three hour incubation in U0126 (DMSO as vehicle control). **(J)** Pattern of nascent *Ebf*  
856 transcripts visualized by *in situ* hybridization with intronic probes (green) at 20 hpf. The nuclear dots  
857 reveal the active transcription sites in the four ASMPs per side in larvae, both control/DMSO- and U0126-  
858 treated from 17 to 20 hpf. **(K)** *Ebf* expression (green) in 18hpf larvae expressing control M-Ras<sup>WT</sup>,  
859 constitutively active M-Ras<sup>G22V</sup> or dominant negative dnFGFR under the control of the T12 element, an  
860 STVC-specific *Tbx1/10* enhancer. Arrows: first heart precursors (FHP); open arrowhead: second heart  
861 precursors (SHPs); closed arrowheads: ASM founder cells (ASMFs); dotted line: midline. **(L)** Proportions of  
862 larvae with wild-type or downregulated expression of *Ebf* at 18 hpf in larvae with Venus (control), M-Ras<sup>WT</sup>,  
863 M-Ras<sup>G22</sup>, or dnFGFR driven by *Tbx1/10* *cis*-regulatory sequence and overexpressed in the STVCs. "n" :  
864 number of individual halves documented per condition.  
865

866



867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895


896

897

898

**Figure 4. M-Ras/MAPK-driven feed-forward subcircuits control the successive activations of *Hand-r*, *Tbx1/10* and *Ebf*.** (A) Proportions of embryo halves with indicated *Tbx1/10* expression patterns following TVC-specific CRISPR/Cas9-mediated mutagenesis of *Neurogenin/Neurog* as a control (*sgCtrl*), and *Hand-r* (*sgHand-r*). TVC-specific overexpression of a CRISPR/Cas9-resistant form of *Hand-r* with mutation in the PAM sequence (*Hand-r<sup>PAMmis</sup>*) rescued *Tbx1/10* expression in the *sgHand-r* "background". TVC-specific overexpression of a constitutively active M-Ras mutant (M-Ras<sup>G22v</sup>) (control: M-Ras<sup>WT</sup>) was sufficient to induce ectopic expression of *Tbx1/10* in the FHPs in *sgCtrl* embryos but not in *sgHand-r* embryos indicating that *Hand-r* is necessary for M-Ras-dependent activation of *Tbx1/10* transcription. (B) Proportions of embryo halves with indicated *Tbx1/10* expression patterns following TVC-specific overexpression of *Hand-r* or a neutral reporter (Venus) and treated from 12 to 15hpf with the MEK inhibitor U0126 (+) or with DMSO (-) as control. *Hand-r* overexpression is not sufficient to rescue loss of *Tbx1/10* expression due to MAPK inhibition indicating that M-Ras/MAPK activity is required in parallel of *Hand-r* expression to activate *Tbx1/10* transcription in the TVC progeny. (C) *Tbx1/10* is necessary downstream of M-Ras/MAPK activity to activate *Ebf* transcription in the TVC progeny. Shown are proportions of *Ebf* expression phenotypes following TVC-specific CRISPR/Cas9-mediated loss of *Tbx1/10* function (*sgTbx1/10*), with *Neurog*-targeting sgRNA as control (*sgCtrl*). Specificity of *Tbx1/10* loss of function was validated through rescue of *Ebf* expression with TVC-specific overexpression of a CRISPR/Cas9 resistant form of *Tbx1/10* (*Tbx1/10<sup>PAMmis</sup>*). Ectopic *Ebf* expression in SHPs in *Tbx1/10<sup>PAMmis</sup>* larvae is explained by precocious misexpression of *Tbx1/10* in the TVC as described in Wang et al, 2013. TVC-specific overexpression of M-Ras<sup>G22v</sup> (M-Ras<sup>G22v</sup>), with wild type M-Ras (M-Ras<sup>WT</sup>) as control, was sufficient to induce ectopic expression of *Ebf* in the cardiac precursors in *sgCtrl* embryos but not in *sgTbx1/10* embryos indicating that *Tbx1/10* is necessary for M-Ras-dependent activation of *Ebf* transcription. (D, E) Proportions (D) and examples (E) of 15hpf larvae halves showing indicated *Ebf* expression phenotypes in *sgCtrl* and *sgHand-r* CRISPR/Cas9 conditions combined with TVC-specific overexpression of a neutral reporter (Venus), *Hand-r<sup>PAMmis</sup>*, or *Tbx1/10*, and with MEK inhibition by U0126 (+) or not (DMSO control (-)). Arrowhead: STVCs, Arrows: FHPs, dotted line: ventral midline (F) Loss of *Hand-r* function impaired the ability of *Tbx1/10* to induce ectopic *Ebf* expression. For simplicity, ectopic expressions in half to all of the cardiac precursors were combined in the same phenotype category. "n=": number of individual halves documented per condition. (G) Summary model of the temporal deployment of FGF/MAPK-driven feed-forward sub-circuits leading to the sequential activations of *Tbx1/10* and *Ebf* in the STVCs and ASMFs, respectively.


899



900




901 **Figure 5. Temporal deployment of the cardiopharyngeal network is partially coupled with**  
902 **cell cycle progression.** (A) Schematic representation of the canonical eukaryotic cell cycle, and actions  
903 of the perturbations used in this study. (B,C) *Tbx1/10* and *Ebf* expression at indicated time points, and  
904 following inhibition of cytokinesis by cytochalasin B treatment at indicated time points. Note that 15 to  
905 19hpf treatment is applied AFTER the first division and birth the FHPs, which do not activate *Ebf* at 19hpf  
906 (right panel, arrows). (D) Inhibition of G<sub>1</sub>/S or G<sub>2</sub>/M blocks TVC division, and reduces *Tbx1/10* expression.  
907 Pictures shows TVCs that have divided in controls but not in experimental cells, with one cell occasionally  
908 turning on *Tbx1/10*, but not the other. Left: the proportions of embryos showing strong *Tbx1/10* expression  
909 is substantially reduced compared to control embryos (e.g. Figure 1, and [\(Wang et al., 2013\)](#)). (E) Inhibition  
910 of G<sub>2</sub>/M in the STVCs by misexpression of *Wee1* using the *Tbx1/10 T6* enhancer inhibits STVC division,  
911 and has a mild impact on *Ebf* expression at 18hpf. Open arrows indicate STVCs that have not divided, but  
912 express high (middle) or low (right) levels of *Ebf*. Left: control larva showing high *Ebf* expression in the  
913 ASMF (closed arrowheads), but neither in the SHPs (open arrowheads) nor in the FHPs (Arrows). (F)  
914 Misexpression of *Wee1* using the *Tbx1/10 T6* enhancer (*Tbx1>Wee1*) inhibits STVC division. Right: the  
915 proportions of embryos showing strong *Lrp4/8*, *Kirri1* or *Dach* expression into late STVCs is reduced  
916 compared to SHPs in control embryos (*T6>NLS::LacZ*) at 18 hpf. Notably, the pan-cardiac marker *Lrp4/8*  
917 is still expressed in FHPs (arrows). Nuclei are marked in red with *Mesp>NLS::lacZ*, membranes in blue  
918 with *Mesp>hCD4::mCherry*, FHP labeled with arrows and SHP with arrowheads. 'n=', number of individual  
919 halves scored per condition. Scale bar, 5 μm. In all image panels, dotted line : ventral midline.  
920



922 **Figure 6. *Ebf* regulation transitions from MAPK-dependent to autoregulative during the**  
923 **early phase of ASMF cycle. (A)** Proportions of 20hpf larva halves showing the indicated number of *Ebf*-  
924 expressing cells following U0126 treatments started at the indicated time points. This indicates that, by  
925 17hpf, *Ebf* expression, which started at ~16hpf, has become largely insensitive to loss of MAPK activity. (B)  
926 Summary lineage diagram and time scale indicating the approximate stages for U0126 and DMSO (control)  
927 treatments for the results shown in (C, D). (C) Control (Ctrl) and *Ebf*-misexpressing embryos fixed at 16hpf,  
928 prior to chemical treatments, and stained for nascent transcripts with an intronic *Ebf* probe. In controls,  
929 the ASMFs (solid arrowhead), but neither the SHPs (open arrowheads) nor the FHPs (arrows), actively  
930 transcribe *Ebf* (green nuclear dots). In Larvae misexpressing the *Ebf* cDNA under the control of the STVC-  
931 specific *Tbx1/10* enhancer, divisions are delayed and STVCs (solid arrowheads) activated transcription of  
932 endogenous *Ebf* loci (green nuclear dots). (D) After 4 hours, U0126 treated ASMFs no longer transcribe *Ebf*  
933 (top right image, solid arrowheads), whereas control DMSO-treated ASMFs do (top left, green nuclear  
934 dots). Upon misexpression of the *Ebf* cDNA in the STVCs and derivatives, ongoing *Ebf* transcription is  
935 detected at 20hpf in both DMSO and U0126-treated cells, and it persists in both ASMFs (solid arrowheads),  
936 and SHPs (open arrowheads). (E, F) Proportions of larvae halves showing the indicated *Ebf* transcription  
937 patterns, in indicated experimental conditions, as illustrated in C and D, respectively.  
938




967



968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983

**Figure S1. Detailed patterns of MAPK activity during early cardiopharyngeal development.** (A) MAPK activation during TVC induction. Close-up views of B7.5 lineage cells marked with Mesp>H2B::mCherry (nuclei) and Mesp>hCD4::mCherry (membranes) and immunostained for dpERK at indicated successive time points between 7 and 10hpf. DpERK staining was not detected in the founder cells at 7hpf, but increased sharply and specifically in the smaller trunk ventral cells (TVCs, open arrows) at 7.5hpf, but not in the larger anterior tail muscles (ATMs). DpERK staining persisted throughout TVC migration (see also B). (B) MAPK activation patterns during cardiopharyngeal fate diversification. DpERK staining was clearly detected in migrating TVCs (open arrows, 11 to 13hpf); in lateral large STVCs (open arrows, 14 to 15hpf), but not in the small median first heart precursors (FHPs, arrows, 14 to 15hpf); in the large lateral atrial siphon muscle founder cells (ASMFs, solid arrowheads, 16 to 17hpf), but neither in the FHPs (arrows), nor in the second heart precursors (SHPs, open arrowheads). (C) Treatment with the MEK inhibitor U0126 from 12 to 15.5hpf abolished dpERK staining in the lateral STVCs, compared to a control treatment with DMSO. Numbers of embryos showing the presented pattern out of the total numbers of embryos are shown.


984



985  
986 **Figure S2 - part 1.**

987 **(A) Effects of perturbations on *Foxf* TVC-specific enhancer activity.** Proportions of  
988 *Mesp>H2B::mCherry*-positive embryos showing *Foxf::bpFog-1>NLS::GFP* activity (i.e. GFP+) in the  
989 indicated conditions : TVC-specific CRISPR/Cas9 mediated loss-of-function of *Hand-r* (sg*Hand-r*), and  
990 corresponding control (Neurogenin/sgCtrl) at 15 hpf ; TVC-specific CRISPR/Cas9 mediated loss-of-  
991 function of *Tbx1/10* (sg*Tbx1/10*) and corresponding control (Neurogenin/sgCtrl) at 18 hpf ; TVC-targeted  
992 dnFGFR embryos (*FoxF::bpFog-1>dnFGFR*) and corresponding control (*FoxF::bpFog-1>NLS::LacZ*) at 15  
993 hpf ; Inhibition of MAPK activity with 4-hour incubations in U0126 (DMSO as vehicle control) at indicated  
994 times. TVCS and their progeny marked with *Mesp>H2B::mCherry* and possible effects on *Foxf* enhancer  
995 activity of these perturbations have been verified with TVC-specific green staining. There were no  
996 significant difference in the proportions of GFP+ embryos between each perturbations and controls. **(B-D)**  
997 **Other markers expressed in the TVC need continuous FGF-MAPK inputs for maintenance.**

998 All panels show the proportions of 12.5hpf embryos halves showing expression of the indicated genes in late  
999 TVCs, following electroporation of either a *Foxf(TVC)>Venus* control of a *Foxf(TVC)>dnFGFR* construct  
1000 that inhibits signaling through FGFR. Wild-type pattern were first reported in ([Razy-Krajka et al., 2014](#)).  
1001




1002  
1003  
1004  
1005  
1006  
1007  
1008

**Figure S2 - part 2.**

**(E-G) Foxf>dnFGFR does not inhibit TVC induction.** TVC-specific expression of dnFGFR (FoxF::bpFog-1>dnFGFR) do not show difference in TVC markers expression in comparison to control (FoxF::bpFog-1>Venus) in early TVC (*Foxf* and *Hand-r* at 8 hpf, *Nkx2-5* at 10 hpf).

Arrows indicate anterior TVCs, adjacent cells on the right are ATMs, which do not express TVC markers.



**Figure S3. Effects of defined FGF-MAPK signaling perturbations on cell division patterns in the cardiopharyngeal lineage.**

(A) Representative phenotype in unperturbed conditions (control plasmid: *Foxf>LacZ*) at 15hpf. TVCs divide asymmetrically and in a medio-lateral orientation.

(B) Representative misoriented TVC division phenotype (*Foxf>dnFGFR*). One TVC divided improperly in the antero-posterior axis.

(C) Proportions of embryo halves showing wild-type vs. orientation or symmetry phenotype, scored at 15hpf. For pharmacological treatments, embryos were incubated in DMSO or U0126 from 12hpf-15hpf. Proportions differ significantly between *Foxf>MRas* and *Foxf>caMRas*, and between DMSO and U0126 treatment conditions (\*\* indicates  $p$ -value < 0.01,  $\chi^2$  test).

(D) Representative phenotype in unperturbed conditions (*FoxF>LacZ*) at 18hpf. STVCs divide in a medio-lateral orientation.

(E) Representative misoriented STVC division phenotype (*FoxF>caMRas*), scored as 'abnormal but can interpret.' STVCs likely divided improperly in the antero-posterior axis.


(F) Proportions of larva halves in *Foxf*(TVC)-driven perturbations showing wild-type pattern vs. orientation and/or symmetry phenotypes, patterns scored at 18hpf as abnormal but interpretable or abnormal/can't interpret.

For pharmacological treatments, larvae were incubated in DMSO or U0126 from 12hpf-18hpf. Proportions differ significantly in all conditions in comparison to the corresponding control (\*\* indicates  $p$ -value < 0.01,  $\chi^2$  test).

(G) Proportions of larva halves in *Tbx1*-driven perturbations showing wild-type pattern vs. orientation and/or symmetry phenotype, patterns scored at 18hpf as abnormal but interpretable or abnormal/can't interpret.


For pharmacological treatments, larvae were incubated in DMSO or U0126 from 15hpf-18hpf. Proportions differ significantly only between *Tbx1>MRas* and *Tbx1>caMRas* conditions (\*\* indicates  $p$ -value < 0.01,  $\chi^2$  test).






1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073

**Figure S4. The constitutively active MEK<sup>S216D, S220E</sup> mutant is sufficient to impose a TVC identity to the whole B7.5 lineage.** (A) Control late tailbud embryo showing the left side B7.5 lineage expressing GFP and a MEK<sup>WT</sup> control under the control of the *Mesp* enhancer. Two TVCs and two ATMs are normally induced, and TVCs migrated into the trunk. (B) Late tailbud embryo showing the left side B7.5 lineage expressing GFP and a MEK<sup>S216D, S220E</sup> mutant under the control of the *Mesp* enhancer. Four cells are observed as having migrated into the trunk, indicating that they have been induced to acquire a TVC fate and migrate, replicating FGF-MAPK gain-of-function phenotypes as described in (Davidson et al., 2006). (C) Proportions of embryo halves showing the indicated phenotypes. Extra migration is interpreted as ectopic induction of the TVC fate in all B7.5 lineage cells. Scale bar ~ 20µm.



**Figure S5. The *Tbx1/10* enhancer has conserved putative Ets binding sites required for reporter gene expression.** (A) Alignment of *Tbx1/10* locus between *Ciona robusta*/*Ciona savignyi* using VISTA. (B) *Ciona* larva (st 26) expressing GFP driven by the *T12* element, a STVC-specific *Tbx1/10* enhancer (green) and *Mesp>H2B::mCherry* to track the B7.5 lineage cell nuclei (red). The *Tbx1/10* enhancer drives the *unc76::GFP* reporter in the STVC progeny, including ASM precursors (ASMPs) (white arrows) and the second heart precursors (SHPs) (white arrowheads). No expression is detected in the first heart precursors (FHPs) (white arrowheads) and anterior tail muscle (ATMs) (orange arrows). (C) Sequence alignment of *Tbx1/10* enhancer between *Ciona robusta*/*Ciona savignyi*. Conserved blocks in the orange boxes with putative Ets binding sites. (D) Proportion of larvae expressing both GFP and mCherry in the STVC progeny when co-electroporated wild-type and mutant *Tbx1/10* reporters lacking the indicated putative Ets binding sites and *Mesp>H2B::mCherry* in comparison to the control (no enhancer, only *Tbx1/10* basal promoter driving *unc::76GFP*). n: number of electroporated larval halves.

1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088




1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100

**Figure S6. Dynamics of *Ebf* upregulation and entrainment by the cell cycle.** (A) Proportions of larva halves fixed at successive time points and showing undivided STVCs, or ASMFs with or without ectopic *Ebf* expression in the SHPs following STVC-specific expression of the G2/M inhibitor Wee1 (+), or a control construct (-). See Figure S6E for an example of ectopic *Ebf* expression in the SHPs (grey labels). Note the sharp increase in % of larva with ASMF between 15.5 and 16hpf, indicating that mitosis occurs primarily during this time window, but is delayed in a majority of larvae upon Wee1 misexpression. (B) Proportions of larva halves with cells showing indicated *Ebf* expression. The numbers (n) for cells expressing Wee1 focus on cells that have not divided (% shown in E), to estimate the dynamics of *Ebf* activation in G2/M-inhibited cells. Control cells consist mostly ASMFs after 15.5hpf as shown in (E). Wee1 and controls distributions differ significantly only at 16 and 16.5hpf (\*\*,  $p < 0.01$ , Chi<sup>2</sup> test), suggesting that Wee1 merely delays the accumulation of *Ebf* transcripts. (A) 15.5hpf Cardiopharyngeal lineage cells

1101 expressing Mesp>H2B::mCherry (red) and control Tbx1/10>unc76::GFP construct (not visible). **Rare**  
1102 **precocious activation of *Ebf* transcription in STVCs.** (C.a) Green nuclear dot indicates nascent *Ebf*  
1103 transcription in an STVC (open arrow), but not the other, and not in the first heart precursors (FHP;  
1104 arrow). (C.b) left pair of nuclei shows an STVC (open arrow) and an FHP (arrow), neither of which express  
1105 *Ebf*, whereas the cousin ASMF (solid arrowhead) shows nascent *Ebf* transcription (green dot). Dotted line :  
1106 midline. (D) Proportions of STVCs and ASMFs showing indicated *Ebf* expression patterns. Note that >90%  
1107 of STVCs do not express *Ebf*, which turns on almost exclusively in ASMFs. (E) Cardiopharyngeal lineage  
1108 cells with *Ebf* expression in the ASMFs (solid arrowheads), and ectopically in the SHP (open arrowheads),  
1109 but not in the FHPs (arrows), following misexpression of *Wee1* using the STVC-specific *Tbx1/10 T12*  
1110 enhancer. Dotted line: midline.  
1111

1112



1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128

**Figure S7. MAPK signaling is necessary for *Ebf* expression only in early ASMF, and cell cycle inputs shorten the MAPK-dependent period.** (A) Proportions of larva halves showing the indicated *Ebf* transcriptional activity (assayed using intronic probes). Batches of larvae expressing *Mesp>H2B::mCherry* were split to be fixed for WMFISH or treated with U0126 at 3 successive time points (15.75hpf, 16hpf or 16.25hpf), and the treated larvae were fixed at 20hpf. This data shows that, although all batches expressed *Ebf* at the beginning of the experiment, only when MEK was inhibited later (16.25hpf) did *Ebf* transcription persist in 20hpf larvae. (B) Proportions of larva halves showing the indicated numbers of *Ebf*+ cells at 20hpf, following expression of the G2/M inhibitor *Wee1* in the STVCs, under the control of the *Tbx1/10 T12* enhancer (+). Negative controls (-) were electroporated with a *Tbx1/10(T12)>Venus* construct. Larvae were also treated with U0126 (+) or DMSO (as negative control, (-)), starting at 17hpf, which corresponds to the transition from a MAPK-dependent to a MAPK-independent autoregulative mode of *Ebf* expression (see Figure 6A). *Wee1*-induced delays in cell cycle progression increased the sensitivity of late *Ebf* expression to MAPK inhibition, further supporting the notion that cell divisions accelerate the transition from MAPK-dependent to MAPK-independent self-activating regulation of *Ebf* transcription.

1129 **REFERENCES**

- 1130 Abu-Issa, R., Smyth, G., Smoak, I., Yamamura, K., Meyers, E.N., 2002. Fgf8 is  
1131 required for pharyngeal arch and cardiovascular development in the mouse.  
1132 *Development* 129, 4613-4625.
- 1133 Aggarwal, V.S., Liao, J., Bondarev, A., Schimmang, T., Lewandoski, M., Locker, J.,  
1134 Shanske, A., Campione, M., Morrow, B.E., 2006. Dissection of Tbx1 and Fgf interactions  
1135 in mouse models of 22q11DS suggests functional redundancy. *Human molecular*  
1136 *genetics* 15, 3219-3228.
- 1137 Alsan, B.H., Schultheiss, T.M., 2002. Regulation of avian cardiogenesis by Fgf8  
1138 signaling. *Development* 129, 1935-1943.
- 1139 Barron, M., Gao, M., Lough, J., 2000. Requirement for BMP and FGF signaling  
1140 during cardiogenic induction in non-precardiac mesoderm is specific, transient, and  
1141 cooperative. *Developmental dynamics : an official publication of the American*  
1142 *Association of Anatomists* 218, 383-393.
- 1143 Beh, J., Shi, W., Levine, M., Davidson, B., Christiaen, L., 2007. FoxF is essential for  
1144 FGF-induced migration of heart progenitor cells in the ascidian *Ciona intestinalis*.  
1145 *Development* 134, 3297-3305.
- 1146 Bertrand, V., Hudson, C., Caillol, D., Popovici, C., Lemaire, P., 2003. Neural tissue in  
1147 ascidian embryos is induced by FGF9/16/20, acting via a combination of maternal  
1148 GATA and Ets transcription factors. *Cell* 115, 615-627.
- 1149 Bondue, A., Lapouge, G., Paulissen, C., Semeraro, C., Iacovino, M., Kyba, M.,  
1150 Blanpain, C., 2008. Mesp1 acts as a master regulator of multipotent cardiovascular  
1151 progenitor specification. *Cell stem cell* 3, 69-84.
- 1152 Bothe, I., Tenin, G., Oseni, A., Dietrich, S., 2011. Dynamic control of head mesoderm  
1153 patterning. *Development* 138, 2807-2821.
- 1154 Brand, T., 2003. Heart development: molecular insights into cardiac specification  
1155 and early morphogenesis. *Developmental biology* 258, 1-19.
- 1156 Brown, C.B., Wenning, J.M., Lu, M.M., Epstein, D.J., Meyers, E.N., Epstein, J.A.,  
1157 2004. Cre-mediated excision of Fgf8 in the Tbx1 expression domain reveals a critical  
1158 role for Fgf8 in cardiovascular development in the mouse. *Developmental biology* 267,  
1159 190-202.
- 1160 Buckingham, M., Vincent, S.D., 2009. Distinct and dynamic myogenic populations in  
1161 the vertebrate embryo. *Current opinion in genetics & development* 19, 444-453.
- 1162 Cai, C.L., Liang, X., Shi, Y., Chu, P.H., Pfaff, S.L., Chen, J., Evans, S., 2003. Isl1  
1163 identifies a cardiac progenitor population that proliferates prior to differentiation and  
1164 contributes a majority of cells to the heart. *Developmental cell* 5, 877-889.
- 1165 Chan, S.S., Hagen, H.R., Swanson, S.A., Stewart, R., Boll, K.A., Aho, J., Thomson,  
1166 J.A., Kyba, M., 2016. Development of Bipotent Cardiac/Skeletal Myogenic Progenitors  
1167 from MESP1+ Mesoderm. *Stem cell reports* 6, 26-34.

- 1168 Chan, S.S., Shi, X., Toyama, A., Arpke, R.W., Dandapat, A., Iacovino, M., Kang, J.,  
1169 Le, G., Hagen, H.R., Garry, D.J., Kyba, M., 2013. Mesp1 patterns mesoderm into  
1170 cardiac, hematopoietic, or skeletal myogenic progenitors in a context-dependent  
1171 manner. *Cell stem cell* 12, 587-601.
- 1172 Chen, L., Fulcoli, F.G., Tang, S., Baldini, A., 2009. Tbx1 regulates proliferation and  
1173 differentiation of multipotent heart progenitors. *Circulation research* 105, 842-851.
- 1174 Choi, C.Y., Lee, Y.M., Kim, Y.H., Park, T., Jeon, B.H., Schulz, R.A., Kim, Y., 1999. The  
1175 homeodomain transcription factor NK-4 acts as either a transcriptional activator or  
1176 repressor and interacts with the p300 coactivator and the Groucho corepressor. *The*  
1177 *Journal of biological chemistry* 274, 31543-31552.
- 1178 Christiaen, L., Davidson, B., Kawashima, T., Powell, W., Nolla, H., Vranizan, K.,  
1179 Levine, M., 2008. The transcription/migration interface in heart precursors of *Ciona*  
1180 *intestinalis*. *Science* 320, 1349-1352.
- 1181 Christiaen, L., Wagner, E., Shi, W., Levine, M., 2009a. Electroporation of transgenic  
1182 DNAs in the sea squirt *Ciona*. *Cold Spring Harbor protocols* 2009, pdb prot5345.
- 1183 Christiaen, L., Wagner, E., Shi, W., Levine, M., 2009b. Isolation of sea squirt (*Ciona*)  
1184 gametes, fertilization, dechoriation, and development. *Cold Spring Harbor protocols*  
1185 2009, pdb prot5344.
- 1186 Christiaen, L., Wagner, E., Shi, W., Levine, M., 2009c. Whole-mount in situ  
1187 hybridization on sea squirt (*Ciona intestinalis*) embryos. *Cold Spring Harbor protocols*  
1188 2009, pdb prot5348.
- 1189 Cinnamon, E., Helman, A., Ben-Haroush Schyr, R., Orian, A., Jimenez, G., Paroush,  
1190 Z., 2008. Multiple RTK pathways downregulate Groucho-mediated repression in  
1191 *Drosophila* embryogenesis. *Development* 135, 829-837.
- 1192 Cinnamon, E., Paroush, Z., 2008. Context-dependent regulation of Groucho/TLE-  
1193 mediated repression. *Current opinion in genetics & development* 18, 435-440.
- 1194 Cooley, J., Whitaker, S., Sweeney, S., Fraser, S., Davidson, B., 2011. Cytoskeletal  
1195 polarity mediates localized induction of the heart progenitor lineage. *Nature cell biology*  
1196 13, 952-957.
- 1197 Cota, C.D., Davidson, B., 2015. Mitotic Membrane Turnover Coordinates Differential  
1198 Induction of the Heart Progenitor Lineage. *Developmental cell* 34, 505-519.
- 1199 Cowley, S., Paterson, H., Kemp, P., Marshall, C.J., 1994. Activation of MAP kinase  
1200 kinase is necessary and sufficient for PC12 differentiation and for transformation of  
1201 NIH 3T3 cells. *Cell* 77, 841-852.
- 1202 Dalton, S., 2015. Linking the Cell Cycle to Cell Fate Decisions. *Trends in cell biology*  
1203 25, 592-600.
- 1204 Davidson, B., 2007. *Ciona intestinalis* as a model for cardiac development. *Seminars*  
1205 *in cell & developmental biology* 18, 16-26.

- 1206 Davidson, B., Levine, M., 2003. Evolutionary origins of the vertebrate heart:  
1207 Specification of the cardiac lineage in *Ciona intestinalis*. Proceedings of the National  
1208 Academy of Sciences of the United States of America 100, 11469-11473.
- 1209 Davidson, B., Shi, W., Beh, J., Christiaen, L., Levine, M., 2006. FGF signaling  
1210 delineates the cardiac progenitor field in the simple chordate, *Ciona intestinalis*. Genes  
1211 & development 20, 2728-2738.
- 1212 Davidson, B., Shi, W., Levine, M., 2005. Uncoupling heart cell specification and  
1213 migration in the simple chordate *Ciona intestinalis*. Development 132, 4811-4818.
- 1214 de Pater, E., Clijsters, L., Marques, S.R., Lin, Y.-F., Garavito-Aguilar, Z.V., Yelon, D.,  
1215 Bakkers, J., 2009. Distinct phases of cardiomyocyte differentiation regulate growth of  
1216 the zebrafish heart. Development 136, 1633-1641.
- 1217 Delsuc, F., Brinkmann, H., Chourrout, D., Philippe, H., 2006. Tunicates and not  
1218 cephalochordates are the closest living relatives of vertebrates. Nature 439, 965-968.
- 1219 Diogo, R., Kelly, R.G., Christiaen, L., Levine, M., Ziermann, J.M., Molnar, J.L.,  
1220 Noden, D.M., Tzahor, E., 2015a. The Cardiopharyngeal Field and Vertebrate Evolution:  
1221 A New Heart for a New Head. Nature in press.
- 1222 Diogo, R., Kelly, R.G., Christiaen, L., Levine, M., Ziermann, J.M., Molnar, J.L.,  
1223 Noden, D.M., Tzahor, E., 2015b. A new heart for a new head in vertebrate  
1224 cardiopharyngeal evolution. Nature 520, 466-473.
- 1225 Dumollard, R., Minc, N., Salez, G., Aicha, S.B., Bekkouche, F., Hebras, C.,  
1226 Besnardeau, L., McDougall, A., 2017. The invariant cleavage pattern displayed by  
1227 ascidian embryos depends on spindle positioning along the cell's longest axis in the  
1228 apical plane and relies on asynchronous cell divisions. eLife 6.
- 1229 Farley, E.K., Olson, K.M., Zhang, W., Brandt, A.J., Rokhsar, D.S., Levine, M.S., 2015.  
1230 Suboptimization of developmental enhancers. Science 350, 325-328.
- 1231 Farley, E.K., Olson, K.M., Zhang, W., Rokhsar, D.S., Levine, M.S., 2016. Syntax  
1232 compensates for poor binding sites to encode tissue specificity of developmental  
1233 enhancers. Proceedings of the National Academy of Sciences of the United States of  
1234 America 113, 6508-6513.
- 1235 Frazer, K.A., Pachter, L., Poliakov, A., Rubin, E.M., Dubchak, I., 2004. VISTA:  
1236 computational tools for comparative genomics. Nucleic acids research 32, W273-279.
- 1237 Gainous, T.B., Wagner, E., Levine, M., 2015. Diverse ETS transcription factors  
1238 mediate FGF signaling in the *Ciona* anterior neural plate. Developmental biology 399,  
1239 218-225.
- 1240 Gandhi, S., Haeussler, M., Razy-Krajka, F., Christiaen, L., Stolfi, A., 2017a.  
1241 Evaluation and rational design of guide RNAs for efficient CRISPR/Cas9-mediated  
1242 mutagenesis in *Ciona*. Developmental biology.



- 1243 Gandhi, S., Haeussler, M., Razy-Krajka, F., Christiaen, L., Stolfi, A., 2017b.  
1244 Evaluation and rational design of guide RNAs for efficient CRISPR/Cas9-mediated  
1245 mutagenesis in *Ciona*. bioRxiv.
- 1246 George, V., Colombo, S., Targoff, K.L., 2015. An early requirement for *nkx2.5* ensures  
1247 the first and second heart field ventricular identity and cardiac function into adulthood.  
1248 *Developmental biology* 400, 10-22.
- 1249 Gopalakrishnan, S., Comai, G., Sambasivan, R., Francou, A., Kelly, R.G., Tajbakhsh,  
1250 S., 2015. A Cranial Mesoderm Origin for Esophagus Striated Muscles. *Developmental*  
1251 *cell* 34, 694-704.
- 1252 Gotoh, N., Laks, S., Nakashima, M., Lax, I., Schlessinger, J., 2004. FRS2 family  
1253 docking proteins with overlapping roles in activation of MAP kinase have distinct  
1254 spatial-temporal patterns of expression of their transcripts. *FEBS letters* 564, 14-18.
- 1255 Gueroult-Bellone, M., Nitta, K.R., Kari, W., Jacox, E., Beule Dausat, R., Vincentelli,  
1256 R., Diarra, C., Rothbacher, U., Dantec, C., Cambillau, C., Piette, J., Lemaire, P., 2017.  
1257 Spacer sequences separating transcription factor binding motifs set enhancer quality  
1258 and strength. bioRxiv.
- 1259 Hasson, P., Egoz, N., Winkler, C., Volohonsky, G., Jia, S., Dinur, T., Volk, T., Courey,  
1260 A.J., Paroush, Z., 2005. EGFR signaling attenuates Groucho-dependent repression to  
1261 antagonize Notch transcriptional output. *Nature genetics* 37, 101-105.
- 1262 Haupaix, N., Abitua, P.B., Sirour, C., Yasuo, H., Levine, M., Hudson, C., 2014.  
1263 Ephrin-mediated restriction of ERK1/2 activity delimits the number of pigment cells in  
1264 the *Ciona* CNS. *Developmental biology* 394, 170-180.
- 1265 Hotta, K., Mitsuhara, K., Takahashi, H., Inaba, K., Oka, K., Gojobori, T., Ikeo, K.,  
1266 2007. A web-based interactive developmental table for the ascidian *Ciona intestinalis*,  
1267 including 3D real-image embryo reconstructions: I. From fertilized egg to hatching  
1268 larva. *Developmental dynamics : an official publication of the American Association of*  
1269 *Anatomists* 236, 1790-1805.
- 1270 Hu, T., Yamagishi, H., Maeda, J., McAnally, J., Yamagishi, C., Srivastava, D., 2004.  
1271 *Tbx1* regulates fibroblast growth factors in the anterior heart field through a reinforcing  
1272 autoregulatory loop involving forkhead transcription factors. *Development* 131, 5491-  
1273 5502.
- 1274 Hudson, C., Darras, S., Caillol, D., Yasuo, H., Lemaire, P., 2003. A conserved role for  
1275 the MEK signalling pathway in neural tissue specification and posteriorisation in the  
1276 invertebrate chordate, the ascidian *Ciona intestinalis*. *Development* 130, 147-159.
- 1277 Hutson, M.R., Zeng, X.L., Kim, A.J., Antoon, E., Harward, S., Kirby, M.L., 2010.  
1278 Arterial pole progenitors interpret opposing FGF/BMP signals to proliferate or  
1279 differentiate. *Development* 137, 3001-3011.
- 1280 Ilagan, R., Abu-Issa, R., Brown, D., Yang, Y.P., Jiao, K., Schwartz, R.J., Klingensmith,  
1281 J., Meyers, E.N., 2006. *Fgf8* is required for anterior heart field development.  
1282 *Development* 133, 2435-2445.

- 1283 Imai, K.S., Levine, M., Satoh, N., Satou, Y., 2006. Regulatory blueprint for a chordate  
1284 embryo. *Science* 312, 1183-1187.
- 1285 Imai, K.S., Satoh, N., Satou, Y., 2002. Early embryonic expression of FGF4/6/9 gene  
1286 and its role in the induction of mesenchyme and notochord in *Ciona savignyi* embryos.  
1287 *Development* 129, 1729-1738.
- 1288 Jeffery, W.R., Chiba, T., Krajka, F.R., Deyts, C., Satoh, N., Joly, J.S., 2008. Trunk  
1289 lateral cells are neural crest-like cells in the ascidian *Ciona intestinalis*: insights into the  
1290 ancestry and evolution of the neural crest. *Developmental biology* 324, 152-160.
- 1291 Jerome, L.A., Papaioannou, V.E., 2001. DiGeorge syndrome phenotype in mice  
1292 mutant for the T-box gene, *Tbx1*. *Nature genetics* 27, 286-291.
- 1293 Kaplan, N., Razy-Krajka, F., Christiaen, L., 2015. Regulation and evolution of  
1294 cardiopharyngeal cell identity and behavior: insights from simple chordates. *Current  
1295 opinion in genetics & development* 32, 119-128.
- 1296 Kattman, S.J., Witty, A.D., Gagliardi, M., Dubois, N.C., Niapour, M., Hotta, A., Ellis,  
1297 J., Keller, G., 2011. Stage-specific optimization of activin/nodal and BMP signaling  
1298 promotes cardiac differentiation of mouse and human pluripotent stem cell lines. *Cell  
1299 stem cell* 8, 228-240.
- 1300 Keduka, E., Kaiho, A., Hamada, M., Watanabe-Takano, H., Takano, K., Ogasawara,  
1301 M., Satou, Y., Satoh, N., Endo, T., 2009. M-Ras evolved independently of R-Ras and its  
1302 neural function is conserved between mammalian and ascidian, which lacks classical  
1303 Ras. *Gene* 429, 49-58.
- 1304 Kelly, R.G., Jerome-Majewska, L.A., Papaioannou, V.E., 2004. The *del22q11.2*  
1305 candidate gene *Tbx1* regulates branchiomeric myogenesis. *Human molecular genetics*  
1306 13, 2829-2840.
- 1307 Kelly, R.G., Papaioannou, V.E., 2007. Visualization of outflow tract development in  
1308 the absence of *Tbx1* using an Fgf10 enhancer trap transgene. *Developmental dynamics* :  
1309 an official publication of the American Association of Anatomists 236, 821-828.
- 1310 Khan, A., Fornes, O., Stigliani, A., Gheorghe, M., Castro-Mondragon, J.A., van der  
1311 Lee, R., Bessy, A., Cheneby, J., Kulkarni, S.R., Tan, G., Baranasic, D., Arenillas, D.J.,  
1312 Sandelin, A., Vandepoele, K., Lenhard, B., Ballester, B., Wasserman, W.W., Parcy, F.,  
1313 Mathelier, A., 2017. JASPAR 2018: update of the open-access database of transcription  
1314 factor binding profiles and its web framework. *Nucleic acids research*.
- 1315 Khoueiry, P., Rothbacher, U., Ohtsuka, Y., Daian, F., Frangulian, E., Roure, A.,  
1316 Dubchak, I., Lemaire, P., 2010. A cis-regulatory signature in ascidians and flies,  
1317 independent of transcription factor binding sites. *Current biology* : CB 20, 792-802.
- 1318 Kuwajima, M., Kumano, G., Nishida, H., 2014. Regulation of the number of cell  
1319 division rounds by tissue-specific transcription factors and Cdk inhibitor during  
1320 ascidian embryogenesis. *PloS one* 9, e90188.

- 1321 Lazic, S., Scott, I.C., 2011. Mef2cb regulates late myocardial cell addition from a  
1322 second heart field-like population of progenitors in zebrafish. *Developmental biology*  
1323 354, 123-133.
- 1324 Lemmon, M.A., Schlessinger, J., 2010. Cell signaling by receptor tyrosine kinases.  
1325 *Cell* 141, 1117-1134.
- 1326 Lescroart, F., Chabab, S., Lin, X., Rulands, S., Paulissen, C., Rodolosse, A., Auer, H.,  
1327 Achouri, Y., Dubois, C., Bondue, A., Simons, B.D., Blanpain, C., 2014. Early lineage  
1328 restriction in temporally distinct populations of Mesp1 progenitors during mammalian  
1329 heart development. *Nature cell biology* 16, 829-840.
- 1330 Lescroart, F., Hamou, W., Francou, A., Theveniau-Ruissy, M., Kelly, R.G.,  
1331 Buckingham, M., 2015. Clonal analysis reveals a common origin between nonsomite-  
1332 derived neck muscles and heart myocardium. *Proceedings of the National Academy of*  
1333 *Sciences of the United States of America* 112, 1446-1451.
- 1334 Lescroart, F., Kelly, R.G., Le Garrec, J.F., Nicolas, J.F., Meilhac, S.M., Buckingham,  
1335 M., 2010. Clonal analysis reveals common lineage relationships between head muscles  
1336 and second heart field derivatives in the mouse embryo. *Development* 137, 3269-3279.
- 1337 Lescroart, F., Mohun, T., Meilhac, S.M., Bennett, M., Buckingham, M., 2012. Lineage  
1338 tree for the venous pole of the heart: clonal analysis clarifies controversial genealogy  
1339 based on genetic tracing. *Circulation research* 111, 1313-1322.
- 1340 Mandal, A., Holowiecki, A., Song, Y.C., Waxman, J.S., 2017. Wnt signaling balances  
1341 specification of the cardiac and pharyngeal muscle fields. *Mechanisms of Development*  
1342 143, 32-41.
- 1343 Mansour, S.J., Resing, K.A., Candi, J.M., Hermann, A.S., Gloor, J.W., Herskind,  
1344 K.R., Wartmann, M., Davis, R.J., Ahn, N.G., 1994. Mitogen-activated protein (MAP)  
1345 kinase phosphorylation of MAP kinase kinase: determination of phosphorylation sites  
1346 by mass spectrometry and site-directed mutagenesis. *Journal of biochemistry* 116, 304-  
1347 314.
- 1348 Marques, S.R., Lee, Y., Poss, K.D., Yelon, D., 2008. Reiterative roles for FGF  
1349 signaling in the establishment of size and proportion of the zebrafish heart.  
1350 *Developmental biology* 321, 397-406.
- 1351 Mazzoni, E.O., Mahony, S., Iacovino, M., Morrison, C.A., Mountoufaris, G., Closser,  
1352 M., Whyte, W.A., Young, R.A., Kyba, M., Gifford, D.K., Wichterle, H., 2011. Embryonic  
1353 stem cell-based mapping of developmental transcriptional programs. *Nature methods*  
1354 8, 1056-1058.
- 1355 Merscher, S., Funke, B., Epstein, J.A., Heyer, J., Puech, A., Lu, M.M., Xavier, R.J.,  
1356 Demay, M.B., Russell, R.G., Factor, S., Tokooya, K., Jore, B.S., Lopez, M., Pandita, R.K.,  
1357 Lia, M., Carrion, D., Xu, H., Schorle, H., Kobler, J.B., Scambler, P., Wynshaw-Boris, A.,  
1358 Skoutchi, A.I., Morrow, B.E., Kucherlapati, R., 2001. TBX1 is responsible for  
1359 cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. *Cell* 104, 619-629.
- 1360 Michailovici, I., Eigler, T., Tzahor, E., 2015. Craniofacial Muscle Development.  
1361 *Current topics in developmental biology* 115, 3-30.

- 1362 Michailovici, I., Harrington, H.A., Azogui, H.H., Yahalom-Ronen, Y., Plotnikov, A.,  
1363 Ching, S., Stumpf, M.P., Klein, O.D., Seger, R., Tzahor, E., 2014. Nuclear to cytoplasmic  
1364 shuttling of ERK promotes differentiation of muscle stem/progenitor cells.  
1365 *Development* 141, 2611-2620.
- 1366 Mosimann, C., Panakova, D., Werdich, A.A., Musso, G., Burger, A., Lawson, K.L.,  
1367 Carr, L.A., Nevis, K.R., Sabeh, M.K., Zhou, Y., Davidson, A.J., DiBiase, A., Burns, C.E.,  
1368 Burns, C.G., MacRae, C.A., Zon, L.I., 2015. Chamber identity programs drive early  
1369 functional partitioning of the heart. *Nature communications* 6, 8146.
- 1370 Nathan, E., Monovich, A., Tirosh-Finkel, L., Harrelson, Z., Rouso, T., Rinon, A.,  
1371 Harel, I., Evans, S.M., Tzahor, E., 2008. The contribution of Islet1-expressing  
1372 splanchnic mesoderm cells to distinct branchiomic muscles reveals significant  
1373 heterogeneity in head muscle development. *Development* 135, 647-657.
- 1374 Nevis, K., Obregon, P., Walsh, C., Guner-Ataman, B., Burns, C.G., Burns, C.E., 2013.  
1375 *Tbx1* is required for second heart field proliferation in zebrafish. *Developmental*  
1376 *dynamics : an official publication of the American Association of Anatomists* 242, 550-  
1377 559.
- 1378 Norton, J., Cooley, J., Islam, A.F., Cota, C.D., Davidson, B., 2013. Matrix adhesion  
1379 polarizes heart progenitor induction in the invertebrate chordate *Ciona intestinalis*.  
1380 *Development* 140, 1301-1311.
- 1381 Park, E.J., Ogden, L.A., Talbot, A., Evans, S., Cai, C.L., Black, B.L., Frank, D.U.,  
1382 Moon, A.M., 2006. Required, tissue-specific roles for *Fgf8* in outflow tract formation  
1383 and remodeling. *Development* 133, 2419-2433.
- 1384 Park, E.J., Watanabe, Y., Smyth, G., Miyagawa-Tomita, S., Meyers, E., Klingensmith,  
1385 J., Camenisch, T., Buckingham, M., Moon, A.M., 2008. An FGF autocrine loop initiated  
1386 in second heart field mesoderm regulates morphogenesis at the arterial pole of the  
1387 heart. *Development* 135, 3599-3610.
- 1388 Patterson, K.I., Brummer, T., O'Brien, P.M., Daly, R.J., 2009. Dual-specificity  
1389 phosphatases: critical regulators with diverse cellular targets. *The Biochemical journal*  
1390 418, 475-489.
- 1391 Pauklin, S., Madrigal, P., Bertero, A., Vallier, L., 2016. Initiation of stem cell  
1392 differentiation involves cell cycle-dependent regulation of developmental genes by  
1393 Cyclin D. *Genes & development* 30, 421-433.
- 1394 Pauklin, S., Vallier, L., 2013. The cell-cycle state of stem cells determines cell fate  
1395 propensity. *Cell* 155, 135-147.
- 1396 Peljto, M., Wichterle, H., 2011. Programming embryonic stem cells to neuronal  
1397 subtypes. *Current opinion in neurobiology* 21, 43-51.
- 1398 Pennati, R., Ficetola, G.F., Brunetti, R., Caicci, F., Gasparini, F., Griggio, F., Sato, A.,  
1399 Stach, T., Kaul-Strehlow, S., Gissi, C., Manni, L., 2015. Morphological Differences  
1400 between Larvae of the *Ciona intestinalis* Species Complex: Hints for a Valid Taxonomic  
1401 Definition of Distinct Species. *PloS one* 10, e0122879.

- 1402 Picco, V., Hudson, C., Yasuo, H., 2007. Ephrin-Eph signalling drives the asymmetric  
1403 division of notochord/neural precursors in *Ciona* embryos. *Development* 134, 1491-  
1404 1497.
- 1405 Prall, O.W., Menon, M.K., Solloway, M.J., Watanabe, Y., Zaffran, S., Bajolle, F.,  
1406 Biben, C., McBride, J.J., Robertson, B.R., Chaulet, H., Stennard, F.A., Wise, N., Schaft,  
1407 D., Wolstein, O., Furtado, M.B., Shiratori, H., Chien, K.R., Hamada, H., Black, B.L.,  
1408 Saga, Y., Robertson, E.J., Buckingham, M.E., Harvey, R.P., 2007. An Nkx2-  
1409 5/Bmp2/Smad1 negative feedback loop controls heart progenitor specification and  
1410 proliferation. *Cell* 128, 947-959.
- 1411 Putnam, N.H., Butts, T., Ferrier, D.E., Furlong, R.F., Hellsten, U., Kawashima, T.,  
1412 Robinson-Rechavi, M., Shoguchi, E., Terry, A., Yu, J.K., Benito-Gutierrez, E.L.,  
1413 Dubchak, I., Garcia-Fernandez, J., Gibson-Brown, J.J., Grigoriev, I.V., Horton, A.C., de  
1414 Jong, P.J., Jurka, J., Kapitonov, V.V., Kohara, Y., Kuroki, Y., Lindquist, E., Lucas, S.,  
1415 Osoegawa, K., Pennacchio, L.A., Salamov, A.A., Satou, Y., Sauka-Spengler, T., Schmutz,  
1416 J., Shin, I.T., Toyoda, A., Bronner-Fraser, M., Fujiyama, A., Holland, L.Z., Holland,  
1417 P.W., Satoh, N., Rokhsar, D.S., 2008. The amphioxus genome and the evolution of the  
1418 chordate karyotype. *Nature* 453, 1064-1071.
- 1419 Racioppi, C., Kamal, A.K., Razy-Krajka, F., Gambardella, G., Zanetti, L., di Bernardo,  
1420 D., Sanges, R., Christiaen, L.A., Ristatore, F., 2014. Fibroblast growth factor signalling  
1421 controls nervous system patterning and pigment cell formation in *Ciona intestinalis*.  
1422 *Nature communications* 5, 4830.
- 1423 Razy-Krajka, F., Lam, K., Wang, W., Stolfi, A., Joly, M., Bonneau, R., Christiaen, L.,  
1424 2014. Collier/OLF/EBF-Dependent Transcriptional Dynamics Control Pharyngeal  
1425 Muscle Specification from Primed Cardiopharyngeal Progenitors. *Developmental cell*  
1426 29, 263-276.
- 1427 Reifers, F., Walsh, E.C., Leger, S., Stainier, D.Y., Brand, M., 2000. Induction and  
1428 differentiation of the zebrafish heart requires fibroblast growth factor 8  
1429 (*fgf8/acerebellar*). *Development* 127, 225-235.
- 1430 Satou, Y., Imai, K.S., Satoh, N., 2004. The ascidian *Mesp* gene specifies heart  
1431 precursor cells. *Development* 131, 2533-2541.
- 1432 Shi, W., Levine, M., 2008. Ephrin signaling establishes asymmetric cell fates in an  
1433 endomesoderm lineage of the *Ciona* embryo. *Development* 135, 931-940.
- 1434 Shi, W., Peyrot, S.M., Munro, E., Levine, M., 2009. FGF3 in the floor plate directs  
1435 notochord convergent extension in the *Ciona* tadpole. *Development* 136, 23-28.
- 1436 Soufi, A., Dalton, S., 2016. Cycling through developmental decisions: how cell cycle  
1437 dynamics control pluripotency, differentiation and reprogramming. *Development* 143,  
1438 4301-4311.
- 1439 Stolfi, A., Gainous, T.B., Young, J.J., Mori, A., Levine, M., Christiaen, L., 2010. Early  
1440 chordate origins of the vertebrate second heart field. *Science* 329, 565-568.
- 1441 Stolfi, A., Gandhi, S., Salek, F., Christiaen, L., 2014a. Tissue-specific genome editing  
1442 in *Ciona* embryos by CRISPR/Cas9. *Development* 141, 4115-4120.

- 1443 Stolfi, A., Lowe, E.K., Racioppi, C., Ristoratore, F., Brown, C.T., Swalla, B.J.,  
1444 Christiaen, L., 2014b. Divergent mechanisms regulate conserved cardiopharyngeal  
1445 development and gene expression in distantly related ascidians. *eLife* 3, e03728.
- 1446 Stolfi, A., Sasakura, Y., Satou, Y., Christiaen, L., Dantec, C., Endo, T., Naville, M.,  
1447 Nishida, H., Swalla, B., Volff, J.-N., Voskoboynik, A., Dauga, D., Lemaire, P., 2014c.  
1448 Guidelines for the Nomenclature of Genetic Elements in Tunicate Genomes. *Genesis*  
1449 under review.
- 1450 Stolfi, A., Wagner, E., Taliaferro, J.M., Chou, S., Levine, M., 2011. Neural tube  
1451 patterning by Ephrin, FGF and Notch signaling relays. *Development* 138, 5429-5439.
- 1452 Tirosh-Finkel, L., Elhanany, H., Rinon, A., Tzahor, E., 2006. Mesoderm progenitor  
1453 cells of common origin contribute to the head musculature and the cardiac outflow  
1454 tract. *Development* 133, 1943-1953.
- 1455 Tirosh-Finkel, L., Zeisel, A., Brodt-Ivenshitz, M., Shamaï, A., Yao, Z., Seger, R.,  
1456 Domany, E., Tzahor, E., 2010. BMP-mediated inhibition of FGF signaling promotes  
1457 cardiomyocyte differentiation of anterior heart field progenitors. *Development* 137,  
1458 2989-3000.
- 1459 Tolkin, T., Christiaen, L., 2016. Rewiring of an ancestral *Tbx1/10-Ebf-Mrf* network  
1460 for pharyngeal muscle specification in distinct embryonic lineages. *Development* in  
1461 press.
- 1462 Tzahor, E., 2009. Heart and craniofacial muscle development: a new developmental  
1463 theme of distinct myogenic fields. *Developmental biology* 327, 273-279.
- 1464 Tzahor, E., Evans, S.M., 2011. Pharyngeal mesoderm development during  
1465 embryogenesis: implications for both heart and head myogenesis. *Cardiovascular*  
1466 *research* 91, 196-202.
- 1467 Tzahor, E., Kempf, H., Mootoosamy, R.C., Poon, A.C., Abzhanov, A., Tabin, C.J.,  
1468 Dietrich, S., Lassar, A.B., 2003. Antagonists of Wnt and BMP signaling promote the  
1469 formation of vertebrate head muscle. *Genes & development* 17, 3087-3099.
- 1470 Tzahor, E., Lassar, A.B., 2001. Wnt signals from the neural tube block ectopic  
1471 cardiogenesis. *Genes & development* 15, 255-260.
- 1472 van Wijk, B., van den Berg, G., Abu-Issa, R., Barnett, P., van der Velden, S., Schmidt,  
1473 M., Ruijter, J.M., Kirby, M.L., Moorman, A.F., van den Hoff, M.J., 2009. Epicardium  
1474 and myocardium separate from a common precursor pool by crosstalk between bone  
1475 morphogenetic protein- and fibroblast growth factor-signaling pathways. *Circulation*  
1476 *research* 105, 431-441.
- 1477 Vitelli, F., Morishima, M., Taddei, I., Lindsay, E.A., Baldini, A., 2002a. *Tbx1*  
1478 mutation causes multiple cardiovascular defects and disrupts neural crest and cranial  
1479 nerve migratory pathways. *Human molecular genetics* 11, 915-922.
- 1480 Vitelli, F., Taddei, I., Morishima, M., Meyers, E.N., Lindsay, E.A., Baldini, A., 2002b.  
1481 A genetic link between *Tbx1* and fibroblast growth factor signaling. *Development* 129,  
1482 4605-4611.

- 1483 von Scheven, G., Alvares, L.E., Mootoosamy, R.C., Dietrich, S., 2006. Neural tube  
1484 derived signals and Fgf8 act antagonistically to specify eye versus mandibular arch  
1485 muscles. *Development* 133, 2731-2745.
- 1486 Wagner, E., Stolfi, A., Gi Choi, Y., Levine, M., 2014. Islet is a key determinant of  
1487 ascidian palp morphogenesis. *Development* 141, 3084-3092.
- 1488 Wang, W., Razy-Krajka, F., Siu, E., Ketcham, A., Christiaen, L., 2013. NK4  
1489 antagonizes Tbx1/10 to promote cardiac versus pharyngeal muscle fate in the ascidian  
1490 second heart field. *PLoS biology* 11, e1001725.
- 1491 Wang, W., Xiang, S., Jullian, E., Kelly, R.G., Satija, R., Christiaen, L., 2017. A single  
1492 cell transcriptional roadmap for cardiopharyngeal fate diversification. *BioRxiv*.
- 1493 Watanabe, Y., Miyagawa-Tomita, S., Vincent, S.D., Kelly, R.G., Moon, A.M.,  
1494 Buckingham, M.E., 2010. Role of mesodermal FGF8 and FGF10 overlaps in the  
1495 development of the arterial pole of the heart and pharyngeal arch arteries. *Circulation*  
1496 *research* 106, 495-503.
- 1497 Watanabe, Y., Zaffran, S., Kuroiwa, A., Higuchi, H., Ogura, T., Harvey, R.P., Kelly,  
1498 R.G., Buckingham, M., 2012. Fibroblast growth factor 10 gene regulation in the second  
1499 heart field by Tbx1, Nkx2-5, and Islet1 reveals a genetic switch for down-regulation in  
1500 the myocardium. *Proceedings of the National Academy of Sciences of the United States*  
1501 *of America* 109, 18273-18280.
- 1502 Weirauch, M.T., Yang, A., Albu, M., Cote, A.G., Montenegro-Montero, A., Drewe, P.,  
1503 Najafabadi, H.S., Lambert, S.A., Mann, I., Cook, K., Zheng, H., Goity, A., van Bakel, H.,  
1504 Lozano, J.C., Galli, M., Lewsey, M.G., Huang, E., Mukherjee, T., Chen, X., Reece-Hoyes,  
1505 J.S., Govindarajan, S., Shaulsky, G., Walhout, A.J.M., Bouget, F.Y., Ratsch, G.,  
1506 Larrondo, L.F., Ecker, J.R., Hughes, T.R., 2014. Determination and inference of  
1507 eukaryotic transcription factor sequence specificity. *Cell* 158, 1431-1443.
- 1508 Whittaker, J.R., 1973. Segregation during ascidian embryogenesis of egg cytoplasmic  
1509 information for tissue-specific enzyme development. *Proceedings of the National*  
1510 *Academy of Sciences of the United States of America* 70, 2096-2100.
- 1511 Witzel, H.R., Cheedipudi, S., Gao, R., Stainier, D.Y., Dobрева, G.D., 2017. Isl2b  
1512 regulates anterior second heart field development in zebrafish. *Scientific reports* 7,  
1513 41043.
- 1514 Woznica, A., Haeussler, M., Starobinska, E., Jemmett, J., Li, Y., Mount, D.,  
1515 Davidson, B., 2012. Initial deployment of the cardiogenic gene regulatory network in the  
1516 basal chordate, *Ciona intestinalis*. *Developmental biology* 368, 127-139.
- 1517 Yagi, H., Furutani, Y., Hamada, H., Sasaki, T., Asakawa, S., Minoshima, S., Ichida, F.,  
1518 Joo, K., Kimura, M., Imamura, S., Kamatani, N., Momma, K., Takao, A., Nakazawa, M.,  
1519 Shimizu, N., Matsuoka, R., 2003. Role of TBX1 in human del22q11.2 syndrome. *Lancet*  
1520 362, 1366-1373.
- 1521 Yasuo, H., Hudson, C., 2007. FGF8/17/18 functions together with FGF9/16/20  
1522 during formation of the notochord in *Ciona* embryos. *Developmental biology* 302, 92-  
1523 103.

1524 Zaffran, S., Frasch, M., 2002. Early signals in cardiac development. *Circulation*  
1525 research 91, 457-469.

1526 Zhang, Z., Huynh, T., Baldini, A., 2006. Mesodermal expression of Tbx1 is necessary  
1527 and sufficient for pharyngeal arch and cardiac outflow tract development. *Development*  
1528 133, 3587-3595.  
1529